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ABSTRACT
The requirements demanded with respect to the potency and safety of novel chemical entities are
increasing and correspondingly the financial investments needed for developing a new drug are
exploding. Finding ways to overcome the poor drug-like properties, such as solubility, permeability and
toxicity are essential in diminishing the numbers of failures, and thus reducing the costs of drug
development. In many cases prodrugs may offer a way to overcome the poor drug-like properties of a
very potent lead and provide the opportunity to convert a non-developable molecule into a potent
candidate for clinical use.
Prodrugs are pharmacologically inactive molecules that require an enzymatic and/or chemical
transformation before release of a pharmacologically active parent drug in vivo. The prodrug approach
can be applied to a variety of drug molecules, administration routes and formulations, and is one way to
improve the physicochemical, pharmaceutical and biopharmaceutical properties of pharmacologically
potent structures and to overcome barriers to a drug's usefulness.
In the present study, several different prodrug structures were synthesized to achieve improved drug
delivery, including hydroxyimines, ethylidene phosphates and monomethyl phosphate esters. The model
drugs used in this study were nabumetone, ketoprofen and propofol. The physicochemical and
pharmaceutical properties of novel prodrug structures, including aqueous solubility, lipophilicity,
chemical stability and enzymatic release of the parent drug were evaluated in vitro and the bioconversion
of the prodrug to the parent drug was further confirmed in vivo in rats.
Hydroxyimine was shown to be bioconverted to the corresponding ketone by microsomal cytochrome
P450-enzymes both in vitro and in vivo and the released nitric oxide evoked no acute liver toxicity after
peroral administration in rats. Hydroxyimine is thus a potential intermediate prodrug structure, especially
for ketone drugs. However, the chemical and the enzymatic hydrolysis rate of different hydroxyimines to
the parent ketone drug varied extensively between the two different model compounds, suggesting that
the chemical environment around the hydroxyimine structure affects to the applicability of hydroxyimine
prodrug structure.
A method to synthesize of 1-chloroethyl phosphates and phosphoramidates was developed. This
method is a versatile and simple way to prepare 1-chloroethyl phosphates and phosphoramidates either
under normal temperature and pressure conditions or using microwave-assisted synthesis. 1-Chloroethyl
phosphates could not be used as starting materials of ethylidene phosphate prodrugs as such. However,
the synthesis method developed for 1-chloroethyl phosphates could be modified to the synthesis of
ethylidene phosphate prodrug of propofol.
Ethylidene phosphate propofol increased the aqueous solubility of propofol and enzymatically released
propofol in vitro and in vivo in rats, thus proving to be a suitable water-soluble prodrug of propofol for
i.v. administration. Bioconversion of the ethylidene phosphate prodrug releases acetaldehyde, which is
less toxic than the formaldehyde released from traditionally used phosphonooxymethyl prodrugs.
The monomethyl phosphate and phosphonooxymethyl ester prodrugs of propofol did not release the
parent drug in vitro or in vivo, probably due to inability of propofol to act as a substrate for the
phosphodiesterases. Thus, the monoalkyl esters of phosphates do not seem to be suitable as versatile
prodrug structures, but more studies with nucleotide-type model compound are needed to confirm this
speculation.
In conclusion, the present study provided useful information of several novel prodrug structures. In
particular, the ethylidene phosphate structure holds a great promise for further development of phosphate
prodrugs.
National Library of Medicine Classification: QV 744, QV 785, QV 38
Medical Subject Headings: Drug Design; Prodrugs / chemical synthesis; Molecular Structure; Drug
Delivery Systems; Ketoprofen; Propofol; Solubility; Drug Stability; Pharmacokinetics; Phosphates;
Microwaves

"Prodrug research needs more imagination and less dependency on what
has been tried in the past".
Valentino J. Stella in Advanced Drug Delivery Reviews, 1996
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1 INTRODUCTION
The drug development process from the target identification to the final product being
marketed is a time and money consuming process, with the total research and
development (R&D) costs reported as being up to 800 million dollars and an average of
10 years (DiMasi et al. 2003). While the dynamic combinatorial chemistry and high-
throughput screening (HTS) technologies are identifying thousands and thousands of
active compounds, the numbers of launched new drugs are declining; only 17-31 new
molecular entities (NMEs) per year was released for marketing by U.S. Food and Drug
Administration (FDA) during 2002-2006 (Owens 2007, Traynor 2003-2007).
The discovery and development of a new drug starts from the identification and
validation of the target protein or receptor (Figure 1.1). A large set of compounds, of
which only approximately 0.1 % will show any activity, is tested against the target to
find possible lead or hit structures for further studies. These lead structures are
optimized in terms of their potency, physicochemical, pharmaceutical and
pharmacokinetic properties in vitro and the activity of the most promising compounds is
tested in vivo yielding to 10 drug candidates for human clinical trials. Finally perhaps
only one out of ten clinically studied drug candidates may reach the market, and as a
whole, the probability for each synthesized compound to reach the market is thus only
one in a million (Balbach and Korn 2004, Hageman 2006, Oprea 2002).
1 000 000 compounds
1000 leads
600
250
50
10 drug candidates
Activity
Selectivity,
solubility, stability
Chemical inspection,
potency
Permeability,
metabolic stability
In vivo activity
1 marketed drug
Phase I-III human testing
Target
identification
and validation
Lead
identification
Lead
optimization and
candidate
identification
Clinical
Phase
Figure 1.1. The drug development funnel (modified from Balbach and Korn 2004,
Hageman 2006 and Oprea 2002).
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What are the reasons for this poor percentage of success in the drug development
process? Often the structures of the potent HTS leads means that they may be difficult
or even impossible to develop or to act as medicines. The poor drug-like properties,
such as solubility and permeability, in addition to toxicity, are among the main causes
for failures during the drug development process (Frantz 2007, Kola and Landis 2004).
Yet, these barriers need not be insurmountable, as they can be often bypassed by using
prodrugs.
Prodrugs are pharmacologically inactive molecules of an active drug molecule that,
prior to exerting a pharmacological effect, require an enzymatic and/or chemical
transformation to release the active parent drug in vivo. Prodrugs can be used to bypass
physicochemical, pharmaceutical, pharmacokinetic and pharmacodynamic barriers to
drug formulation and delivery, such as poor aqueous solubility, chemical instability,
insufficient oral absorption, rapid presystemic metabolism, inadequate tissue
penetration, toxicity and local irritation (Stella 2006, Stella et al. 1985).  Currently, 5-7
% of all approved drugs worldwide can be classified as prodrugs and in the years 2001
and 2002 approximately 15 % of all new launched drugs were prodrugs (Stella 2004,
2006).
Prodrug structures have been mostly developed using hydroxyl, amine and carboxyl
functionalities, but the possibilities to use prodrugs are not restricted to a few groups of
structures. Furthermore, as the diversity and data of possible prodrug structures
increase, the threshold to use prodrugs becomes reduced. The objective of this study
was to design and synthesize novel prodrug structures including a hydroxyimine and
several phosphate prodrugs, as well as to evaluate their usefulness as potential prodrug
structures in vitro and in vivo.
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2 REVIEW OF LITERATURE
2.1 Drug-like properties of compounds
For a drug candidate to be sufficiently bioavailable and ultimately a commercial
success, its pharmacodynamic activity needs to be in consistent with its structural,
physicochemical and biological properties (Li 2001, Lipinski 2000, Sugiyama 2005).
Drug-like properties are characteristics of compounds, which need to be in balance to
make compounds suitable to act as drugs. Structural properties, such as molecular size
and hydrogen bonding capacity affect the physicochemical properties, such as solubility
and lipophilicity and are contributers to the unique biological properties of each
compound (Table 2.1) (Chan and Stewart 1996, Kerns and Di 2003). Due to this
complex set of drug properties, no strict line for each characteristic can be drawn.
However, classifications and proposals for the optimal properties of the majority of
drug-like compounds have been frequently described in the literature (Chan and Stewart
1996, Lipinski 2000, Lipinski et al. 1997, Oprea 2002, Walters and Murcko 2002,
Wenlock et al. 2003). In a simplified form, it can be said that "druggable compounds
should be such that they can be delivered effectively to the target tissues and cells"
(Sugiyama 2005).
Table 2.1. The key properties of drug-like compounds (Kerns and Di 2003, Sugiyama
2005).
o Structural or molecular properties:
§ Molecular weight
§ Hydrogen bonding
§ Polarity
o Physicochemical properties:
§ Solubility and dissolution
§ Permeability and lipophilicity
§ Stability
§ pKa
o Biological properties:
§ Absorption, distribution, metabolism, excretion (ADME)
§ Transporters, plasma protein binding, CYP inhibition
§ Toxicity and safety
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Poor drug-like properties are probably the most common reason for the failures in the
drug development. In 2000, approximately 40 % of attritions could be traced to poor
drug-like properties (mainly pharmacokinetic and safety reasons) (Kola and Landis
2004). Instead of developing methods for screening the drug-like properties of lead
compounds, much more investments are focused on screening for new biologically
active drug molecules which often possess poor drug-like properties (Li 2001). The in
vitro testing of leads in HTS is no longer restricted due to poor solubility in the aqueous
test media. Nowadays even extremely insoluble compounds can be tested and profiled
(Di and Kerns 2006, Lipinski et al. 1997). Thus, it is worth asking, whether the early-
stage “druggability” screening should precede the biological activity screening (Lipinski
2000, Waterbeemd et al. 2001).
The screening against the drug-like properties has been named as druggability
screening (Lipinski 2000), as property-based drug design (Waterbeemd et al. 2001), as a
quantitative integrated drug selection method (QIDSM) (Sugiyama 2005) or as
pharmaceutical profiling (Di and Kerns 2005, Kerns and Di 2003). All together, these
terms include the in vitro, in vivo and in silico screening against physicochemical,
molecular, ADME-, PK- and safety properties of drug compounds (Kerns and Di 2003,
Sugiyama 2005). The aim of these screens is not to find a compound superior with all
criteria, but to serve as filters when selecting the best candidate for further studies.
These screens could also shorten the time for a drug candidate to reach the market by
combining the discovery and development sections. An appreciation that drug-like
properties of structural hits, leads and drug candidates are intrinsic properties of the
molecules (Borchardt et al. 2006) might bring the "development-thinking" also to the
lead discovery stage.
2.1.1 ADME/Tox
Many factors contribute to the therapeutic efficacy and usability of drugs e.g. ADME-
Tox or ADMET (absorption, distribution, metabolism, excretion and toxicity). A
compound has sufficient ADME-Tox properties, if it is soluble and chemically stable in
the gastrointestinal tract or in its dosage form, it can be absorbed from its site of
administration, it is lipophilic enough to permit membrane penetration and distribution
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to the target tissues, it is not metabolized too rapidly in the liver or in the other
extrahepatic tissues, it is not excreted too rapidly from the body via renal or extrahepatic
clearance mechanisms and its toxicity profile is acceptable for the disease in question
(Borchardt et al. 2006, Stella 2006).
Often the ADME properties and suitability of drug compounds for oral administration
are defined by the term bioavailability. Bioavailability is defined as that fraction of an
orally administered drug that reaches the systemic circulation (Agoram et al. 2001), but
it may as well be expanded to parenteral administration routes, if also the distribution,
metabolism and excretion of drug compounds are considered. Bioavailability also
involves intestinal absorption and distribution, which are dependent on the drug
stability, dissolution, solubility, permeability and dosage forms, first-pass metabolism
and various clearance mechanisms (Agoram et al. 2001, Amidon et al. 1995, Chan and
Stewart 1996).
2.1.1.1 Absorption
The most important segments of the GI-tract for drug absorption are the stomach and
small intestine. The stomach is mainly responsible for breaking down large molecules,
which are then absorbed more easily from the small intestine. The small intestine
consists of three different parts: duodenum, jejunum and ileum (Waterbeemd et al.
2001). The duodenum connects the stomach to jejunum, in which the absorption mainly
takes place (Avdeef 2003). The wall of jejunum is covered with fingerlike projections
called villi, which are populated with millions of microvilli. These structures increase
the absorptive surface area of the intestine over 600-fold (Avdeef 2003, Chan and
Stewart 1996, Waterbeemd et al. 2001). The pH of the GI-tract varies from the acidic
pH of the stomach to the neutral pH of the small intestine. The gastrointestinal pH is
dependent on whether the subject is in the fed or fasted states, i.e. pH changes in
response to food consumption. The pH is also affected by age, pathophysiological
conditions and concurrent drug therapy (Hörter and Dressman 1997).
Absorption across the biological membranes can occur via four different pathways as
illustrated in Figure 2.1: passive transcellular and paracellular absorption, carrier-
mediated absorption and receptor-mediated endocytosis (Chan and Stewart 1996,
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Lehninger et al. 1993). Passive transcellular absorption is the most common route for
absorption of drug molecules through the intestinal mucosal membranes (Chan and
Stewart 1996). It occurs by diffusion through the lipid bilayer and since it is driven by a
concentration gradient, it does not require energy (Lehninger et al. 1993, Li 2001).
Paracellular absorption occurs by diffusion through the tight-junctions between cells
and is a route for absorption of very polar compounds (Taylor 1996). Carrier-mediated
and receptor-mediated endocytosis are active or facilitated transport mechanisms that
require energy and a specific carrier receptor or protein on the cell surface (Lehninger et
al. 1993).
Apical,
Intestinal
lumen
Basolateral,
Plasma
Intestinal
mucosal cell
Passive
transcellular
diffusion
Passive
paracellular
diffusion
Receptor-
mediated
endocytosis
Carrier-
mediated
endocytosis
Efflux
pumps
Figure 2.1. Pathways of transport of drugs across biological membranes (modified from
Chan and Stewart 1996, Lehninger et al.  1993, Taylor 1996).
Passive diffusion requires that a drug molecule is dissolved in the aqueous media of
the GI content, since only the dissolved molecule can diffuse across the membranes.
The compound needs to be stable at the site of absorption and also to be able to partition
into the lipid bilayer of the gut wall as well. Absorption is thus dependent on the
lipophilicity, intrinsic aqueous solubility, surface area of a gut and molecular weight of
the drug molecule (Navia and Chaturvedi 1996, Taylor 1996). The most important
physicochemical properties for passive absorption of drugs from GI-tract are aqueous
solubility and lipophilicity, which will be discussed in more detail in chapter 2.1.3.
In addition to the receptors and proteins responsible for the active transport of drug
molecules across the intestinal membrane, the human intestinal epithelium also
expresses efflux proteins that limit drug absorption and secrete intracellularly formed
metabolites back into the intestinal lumen (Figure 2.1). One well known example of this
kind of efflux pump is P-glycoprotein (P-gp) (Lennernäs 2003, Waterbeemd and Smith
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2001, Waterbeemd et al. 2001). The expression of P-gp is localized to the apical
surfaces of the gut wall epithelium, where the pump acts by preventing the absorption of
drug molecules and other xenobiotics into the systemic circulation. Carrier-mediated
intestinal efflux may be one of the major reasons for incomplete absorption and the
variable bioavailability of drugs (Lennernäs 2003, Waterbeemd and Smith 2001).
2.1.1.2 Distribution
After a drug has reached the circulation by either being absorbed from the GI-tract or
via some other administration route, it will pass through the endothelium of the
capillary and distribute into tissues (Thakker 2006). The distribution of the compound
into the body is described by the term "volume of distribution", which is defined as the
entire dose of the drug in the body (mg) divided by the concentration of the drug in
plasma (mg/l). The distribution is dependent on several structural and physicochemical
properties (molecular size, logP, H-bonding, charge state etc.) of a drug molecule, its
ability to serve as a substrate for influx and efflux transporters and the binding of drug
molecule to plasma proteins (Thakker 2006, Waterbeemd and Smith 2001). In general,
the volume of distribution increases with increasing lipophilicity, but the charge state
can also influence the volume of distribution of drug molecules; basic compounds,
which have the largest volume of distribution, are mainly found in the tissues, while the
acidic molecules with the smallest volume of distribution are mainly located in plasma
and are more susceptible to elimination via liver and kidneys (Waterbeemd et al. 2001).
Drug distribution is an important factor when targeting a drug to a specific tissue,
such as the brain which is separated from the blood by the complex blood-brain barrier
(BBB). The BBB is formed of the capillary endothelial cells packed with epithelial-like
high-resistance tight junctions, which prevent the transport of hydrophilic and large
molecular weight compounds from the circulation to the brain tissue  (de Boer and
Gaillard 2007, Waterbeemd and Smith 2001). If a drug is to penetrate the BBB, it needs
to be either sufficiently lipophilic to undergo passive diffusion across lipid-membranes
or alternatively it has to be a substrate of some of the active transport systems present in
the BBB (de Boer and Gaillard 2007, Pajouhesh and Lenz 2005). In contrast, drugs
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designed for effects on peripheral organs and tissues should not be able to cross the
BBB to avoid CNS side-effects (Alavijeh et al. 2005).
2.1.1.3 Metabolism
The liver is the major organ for drug metabolism, but metabolism occurs also in GI-tract
and to some extent in lungs, skin and kidneys (Li 2001). The hepatic liver metabolism
can be divided into two main groups, phase I oxidation reactions catalyzed by
cytochrome P450-enzymes (first-pass metabolism) and phase II conjugation reactions
catalyzed by several enzymes e.g. UDP-glucuronosyl transferases, sulfotransferases and
glutathione S-transferases (Li 2001, Testa and Cruciani 2001). In addition, the
widespread expression of CYP3A4 in the gut wall epithelium makes it an effective
barrier preventing the absorption of drug molecules. It is believed that CYP3A4 and P-
glycoprotein may act together and limit oral absorption since the CYP3A4 can
metabolize those substrates effluxed back to the gut lumen by P-gp (Lennernäs 2003,
Waterbeemd and Smith 2001).
The consequences of drug metabolism can be both pharmacodynamic (the production
of active, inactive or toxic metabolites) and pharmacokinetic (effects on the duration of
action of the drug, inhibition or induction of the drug metabolism or effects on the
different pharmacokinetic properties of the metabolites) (Testa and Cruciani 2001).
Drug metabolism is involved in many important properties of drug molecules, such as
metabolic stability and clearance, drug-drug interactions, clearance mechanisms and
drug toxicity (Li 2001, Yengi et al. 2007). Metabolism and metabolic enzymes play also
crucial role in the activation of prodrugs, this will be discussed in chapter 2.2.
2.1.1.4 Excretion
Excretion, elimination or clearance of a drug molecule from the body starts immediately
after the drug has entered the circulation. The term "clearance" consists of metabolism
(hepatic metabolic clearance, see above) (Liu and Pang 2006, Obach 2001) and the
elimination of the unchanged drug molecule (renal clearance) (Shitara et al. 2006,
Waterbeemd et al. 2001). Thus, two organs are mainly responsible for clearance i.e. the
liver and the kidney. Renal clearance occurs via filtration of the blood in the glomerulus
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of the kidneys and the further reabsorption of the compounds from the kidney tubule
back to the systemic circulation. Compounds may also be secreted from the circulation
to the proximal tubule by active transport mechanisms via carrier-mediated transport
receptors (Shitara et al. 2006).
The molecular weight of a drug molecule determines whether it can be filtered
through the glomerulus. Molecules with MW greater than 50 000 cannot pass the
glomerulus (e.g. drug bounded to the plasma proteins) (Janku 1993). Unlike glomerular
filtration, the tubular reabsorption occurs via lipid membranes and is thus limited by the
lipophilicity of the compounds (Janku 1993, Waterbeemd et al. 2001). Compounds with
low lipophilicity (log D < 0) are not able to reabsorb across the tubular membrane and
are eliminated in the urine (Waterbeemd et al. 2001). Thus, hydrophilic compounds
with a molecular weight below 50 000 and log D < 0 are often eliminated more easily
intact whereas more lipophilic compounds tend to undergo metabolic conversion to a
more easily excreted form (Waterbeemd et al. 2001).
2.1.1.5 Toxicity
Drug toxicity issues were the reason for 30 % of failures in the pharmaceutical industry
in 2000 (Kola and Landis 2004) and the withdrawals of marketed or investigated drugs,
such as torcetrapib, ximelagatran (Exanta®) and rofecoxib (Vioxx®) due to safety
concerns have been common occurences in recent years (Frantz 2007). The toxic effects
can be divided into genotoxicity, carcinogenicity, reproductive toxicity, target organ
toxicity and local toxicity (Bentley 2001). Toxicity may be specie-specific, organ-
specific and it can arise, when the drug has been used for the long period of time (Li
2001). Toxic effects may be a result of the chemical structure of the drug or its
metabolites or they can be attributable to exaggeration of the desired pharmacological
activity (Bentley 2001).
The toxicity of the drug molecule is difficult to predict, but there are several known
substructures that are prone to form reactive metabolites as reviewed by Nassar and
coworkers (Nassar et al. 2004). The reactive metabolites formed from these
substructures are usually unstable and undergo rapid reaction to more stable metabolites
(Nassar et al. 2004).  In addition to the structural properties, also many in vitro
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experimental assays can be used to evaluate possible toxicity of a drug (Bentley 2001,
Nassar et al. 2004).
2.1.2 Methods for predicting the drug-likeness
Several methods to identify the drug-like properties of drugs have been described in the
literature (Chan and Stewart 1996, Lipinski 2000, Lipinski et al. 1997, Oprea 2002,
Walters and Murcko 2002, Wenlock et al. 2003), of which the Lipinski’s rule of 5 and
the biopharmaceutics classification system (BCS) are presented below as examples.
Both the rule of 5 and the BCS are methods or guidances for the indicative screening of
the sufficient drug-like properties and they can be helpful during the early-stage
discovery and development.
The rule of 5 was published in 1997 by Dr Christopher Lipinski (Lipinski et al. 1997).
It states four characteristics, H-bond donors and acceptors, molecular weight and logP
(Table 2.2), that are usually needed to make molecules more drug-like or orally active.
It also helps to predict oral absorption or permeation of a drug molecule (Lipinski et al.
1997). The idea behind the rule of 5 is the ability to identify possible drug candidates
from the ADME point of view, which is at least as important as their biological receptor
activity when considering orally administered drugs with real therapeutic potential
(Lipinski 2000).
The results from the rule of 5 -calculations are only indicative, meaning that a drug
molecule with values outside the rule of 5 does not automatically have poor
bioavailability. It should be viewed more as a quantitative predictor, it gives a warning
that poor absorption or permeability is possible, and thus, helps to highlight potential
pitfalls in drug properties (Lipinski et al. 1997, Waterbeemd et al. 2001).
Table 2.2. The rule of 5 (Lipinski et al. 1997).
Poor absorption or permeation of a drug is more likely when
o there are more than 5 H-bond donors
o there are more than 10 H-bond acceptors
o MW is greater than 500
o calc.  logP is greater than 5 (or measured logP is greater than 4.15)
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The biopharmaceutics classification system (BCS) is a scientific framework for the
classification of drug substances based on their aqueous solubility and intestinal
permeability (Amidon et al. 1995). It was provided by FDA in 1995 with the objective
of helping predict, whether there is a correlation between in vitro dissolution and in vivo
bioavailability and whether some of the bioequivalence studies could be replaced by in
vitro tests (Amidon et al. 1995, FDA 2006).
BCS takes into account three major factors, dissolution, solubility and intestinal
permeability that influence the rate and extent of drug absorption from immediately
release (IR) solid dosage forms (Table 2.3). The solubility of a drug substance is
determined under physiological pH conditions (pH 1-7.5) by either a shake-flask or
titration method and the permeability is determined in human subjects using
pharmacokinetic studies (mass balance, absolute BA), intestinal permeability methods
and instability-studies in the GI tract (FDA 2000). After the measurement of these three
properties, the drug can be classified into one of four groups (Table 2.4) (Amidon et al.
1995, FDA 2000).
Table 2.3. Physicochemical / biopharmaceutical properties affecting to the rate and
extent of drug absorption from immediately release (IR) solid dosage forms according
to BCS (FDA 2000).
o Dissolution
§ Rapidly dissolving drug = no less than 85 % of the labelled
amount of the drug substance dissolves within 30 min
o Solubility
§ Highly soluble drug = highest dose strength is soluble in 250
ml or less of aqueous media (pH 1-7.5)
o Intestinal permeability
§ Highly permeable drug = the extent of absorption in humans is
90 % or more of an administered dose on a mass balance
determination or in comparison to an intravenous reference
dose
The classification of drugs by the BCS offers an opportunity to predict the absorption
of the drug from the GI-tract. A drug in class I having high solubility and high
permeability is most likely to have a sufficient absorption, while a drug in class IV
having both low solubility and low permeability will require much more studies before
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it can be demonstrated that the absorption will be adequate for oral administration
(Amidon et al. 1995).
Table 2.4. The Biopharmaceutics drug classification system.
Class Solubility / Permeability Properties
I High / High - The drug is well absorbed
- Dissolution or gastric emptying is
rate-limiting step of absorption
II Low / High - Dissolution is rate-limiting step of
absorption
III High /Low - Permeability is rate-limiting step of
absorption
IV Low / Low - Significant problems for effective
oral drug delivery
2.1.3 The crucial physicochemical properties of drugs
Passive transcellular absorption requires a drug molecule to be able to dissolve into the
aqueous media of the GI content, to be soluble and stable at the site of absorption and to
be able to partition into the lipid membrane of the gut wall. Absorption is thus
dependent on the lipophilicity, intrinsic aqueous solubility, surface area and molecular
weight of the drug molecule (Taylor 1996, Navia et al 1996). In addition to the situation
for oral absorption, adequate solubility is also necessary for the intravenous
administration, since the therapeutic dose needs to be dissolved before administration
(Fahr et al. 2005). An inadequate balance between solubility and lipophilicity also leads
to poor permeation across the stratum corneum of the skin (Sloan and Wasdo 2003,
Sloan et al. 2006), the corneal barrier in the eye (Järvinen and Järvinen 1996) and the
BBB in the central nervous system (Anderson 1996). Aqueous solubility and
lipophilicity are interrelated with each other such that often the lipophilicity of a highly
soluble compound is low and vice versa. Thus, finding a suitable balance between these
characteristics is essential if one wishes to obtain drug-like compounds.
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The relationship between solubility, lipophilicity and absorption of drugs across the
biological membranes can be explained by Fick’s first law (equation 1) (Amidon et al.
1995).
www CPdt
dmJ ´== Equation 1.
Jw is the drug flux through the membrane (mass/area/time), Pw is the permeability
coefficient of the intestinal wall and Cw is the drug concentration at the intestinal
surface. Fick’s first law shows that as the solubility (and thus concentration) and the
permeability of the drug increases, also the total flux across the biological membrane
will increase. These two important properties, solubility and permeability have been
discussed in more detail below.
2.1.3.1 Dissolution and aqueous solubility
Drug dissolution is the prerequisite and often the rate-limiting step for the effective drug
absorption and clinical response, since only dissolved drug can be absorbed through the
biological membrane and be transported to its site of action (Amidon et al. 1995, Hörter
and Dressman 1997, Waterbeemd et al. 2001). A slow dissolution rate may lead to the
situation in which the time available for a drug to transit to the absorption site in the GI-
tract is too short for complete dissolution, thus diminishing the bioavailability of the
drug (Hörter and Dressman 1997). The dissolution rate is affected by the solubility of
the drug in the GI content, the pH of the solvent and the structural and physicochemical
properties of drug molecules (e.g. molecular weight, the shape of a molecule, number of
H-bonds). Also drug diffusivity, the surface area of the solid wetted by the luminal
fluids and GI hydrodynamics can influence on the drug dissolution from a solid dosage
form (Hörter and Dressman 1997).
The dissolution rate can be calculated from the Noyes-Whitney-equation (equation 2),
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dXDR d Equation 2.
in which DR is the dissolution rate, A is the surface area available for the dissolution, D
is the diffusion coefficient of the drug, h is the diffusion layer thickness, Cs is the
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saturation solubility of the drug, Xd is the amount of the dissolved drug and V is the
volume of the dissolution media (Hörter and Dressman 1997). The Noyes-Whitney
equation indicates that the saturation solubility, the concentration of the dissolved drug
and the thickness of the diffusion layer are the factors determining the concentration
gradient across the diffusion layer, and thus have a great influence on the dissolution
rate of the drug (Hörter and Dressman 1997).
Saturation solubility Cs describes the concentration of a drug molecule that can be
dissolved in a solvent to reach the equilibrium between the solid phase and the solute
(Martin 1993). Solubility is affected by the physicochemical and structural properties of
a drug molecule and the surrounding solvent, including molecular weight, the shape of
the molecule, the melting point, lipophilicity, the molecule's H-bonding with the
solvent, intra- and intermolecular H-bonding, ionic charge, pKa and counter ion, the pH
of the surrounding GI fluids, polymorphism and the surfactants of the drug formulation
(Amidon et al. 1974, Avdeef 2003, Chan and Stewart 1996, Hörter and Dressman 1997,
Lipinski 2000). A high molecular weight, lipophilicity and tight crystal packing usually
indicates poor solubility (Amidon et al. 1974, Hörter and Dressman 1997) but
increasing the H-bonding capacity often leads to better solubility (Chan and Stewart
1996). The charge state and pKa have a major impact on the solubility of acids and
bases, since their solubility changes as a function of the pH: the solubility of a weak
acid is enhanced at a pH above its pKa-value and the solubility of weak base is
enhanced at a pH below its pKa. The intrinsic solubility of the ionized form is greatly
increased when compared to unionized form at pH of pKa + 1 for weak acids and pKa –
1 for weak bases (Hörter and Dressman 1997).
For parenteral administration, a solubility of at least 10 mg/ml is usually needed for
adequate formulation of drugs (Stella 2006). The case of oral administration is more
complex since the absorption, and thus, the bioavailability is the sum of solubility and
permeability of the drug. The limited volume of the gastric fluids to dissolve the drug
dose quantifies the required solubility with the correlation termed as the dose-solubility
ratio. This term describes the volume of GI fluid that is needed to dissolve the
administered drug (Hörter and Dressman 1997). The relevant solubility is also limited
by the permeability of the drug, meaning that solubility required for sufficient
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absorption and bioavailability is greater for a drug with low permeability and vice versa
(Lipinski 2000). This correlation of the minimum acceptable solubility between the
permeability and the dose is well illustrated in Figure 2.2 (Lipinski 2000). Figure 2.3
describes the solubility needed for low, medium and high permeability drugs at doses
0.1, 1.0 and 10 mg/kg. For example, if the solubility of a poorly permeable orally
administered drug at a dose of 1 mg/kg is greater than 207 ?g/ml, then solubility will
not limit the absorption. At a similar dose, a drug with high permeability requires a
solubility of only 10 ?g/ml (Lipinski 2000).
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Figure 2.2. Minimum acceptable solubility in ?g/ml. Bars show the minimum solubility
for low, medium, and high permeability (Ka) at different clinical doses (Lipinski 2000).
A drug with poor solubility and dissolution representing the limiting step of
absorption does not mean that it is not developable (Huang and Tong 2004). Poor
aqueous solubility can be enhanced by several approaches. Changes to the formulation
of the drug can improve the solubility by altering the physical factors, such as changing
the particle size and the crystal structure, by adding cosolvents and surfactants to the
formulation and by using amorphous material or salt formulations (Davis 2005, Huang
and Tong 2004, Strickley 2004). Cyclodextrins can be used to enhance the aqueous
solubility by complexation of the drug molecules inside cyclodextrin inclusion
complexes. The outside of the oligosaccharide molecule of cyclodextrin is polar and
30
inside is nonpolar, forming a central cavity. The poorly soluble drug molecule can be
complexed to the central cavity, which makes it soluble in aqueous media (Loftsson and
Brewster 1996, Loftsson and Duchene 2007). However, probably the most promising
approach for the enhancement of the aqueous solubility is prodrug technology which
will be discussed in chapter 2.2.
2.1.3.2 Lipophilicity and permeability
The ability of a drug to passively diffuse across the cell membrane by the transcellular
route requires the drug molecule to enter into the phospholipid bilayer and then travel
from the apical to the basolateral side of the cell, either through the cytoplasmic
aqueous phase or along the lipid membranes of the cell (Krämer 1999). The
permeability of drugs across biological membranes is dependent on the lipophilicity and
diffusion coefficient, as can be seen from equation 3:
h
PCDPptc
´
= Equation 3.
Pptc is passive transcellular permeability, D is the diffusion coefficient, PC is the
partition coefficient between the membrane and the luminal fluid and h is the thickness
of the membrane. This equation when combined with Fick's first law (equation 1) shows
that as the lipophilicity, and thus, the partition coefficient of the drug increases, also the
permeability and finally the total flux of the drug across the membrane increases
(Taylor 1996).
Lipophilicity refers to the ability of the drug molecule to partition between two
immiscible solutions, such as water and lipid-like solutions (such as 1-octanol). In a
similar manner to solubility, lipophilicity is the sum of different physicochemical
characteristics, such as molecular weight, intra- and intermolecular H-bonding, polar
surface area, ionic charge, pKa and counter ion (Kramer 1999, Waterbeemd et al. 2001).
Lipophilicity increases with the elevation in the molecular weight and decreases with
the increase of H-bonding capacity and polar surface area (Chan and Stewart 1996,
Kramer 1999). Also lipophilicity, again similar to solubility, is dependent on the pH in
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an inverse manner; ionization of the compound usually leads to decreased lipophilicity
(Comer and Tam 2001).
Lipophilicity of drug molecules is most often estimated by 1-octanol/water partition
(logP) and distribution (logD) coefficients (Waterbeemd et al 2001). The term logP is
used when all the solute is in the neutral state and the logD is used when pH causes part
or all of the solute to be ionized (Kerns et al 2003). To achieve sufficient membrane
permeation by a passive transcellular mechanism, the logD values are generally between
0-3 and molecular weight < 550. On the other hand, good permeation of the drug
molecule with a negative logP value points to the involvement of carrier-mediated
transport (Navia et al 1996). However, the permeability of a drug across the biological
membrane cannot be predicted exclusively by lipophilicity, instead the specific
permeation assays using the calculation models (Waterbeemd 2001) and biological
models, such as Caco-2 cell lines (Kretz and Probst 2001), artificial membrane
permeability assays (PAMPA) (Kansy et al. 2001) and biological BBB-models (Krämer
et al. 2001) are needed to predict the permeability into the tissue in question.
Poor lipophilicity can be enhanced by expanding the time that the drug resides in the
GI-tract by dietary components (Singh 1999), by adding bioadhesive polymers such as
chitosans (Takishima et al. 2002) or by prolonging gastroretention using microparticles
(Burton et al. 1995) or swelling systems (Chen et al. 2000). However, many of these
systems are still being investigated and problems, such as safety and effectiveness
require clarification (Davis 2005). A more interesting and perhaps also a more
straightforward approach for the enhancement of lipophilicity, and thus, better
membrane permeation is to resort to the prodrug technology, which is discussed in more
detail in chapter 2.2.
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2.2 Prodrugs
Prodrugs have become an established concept and a powerful tool in optimizing the
pharmacologically potent structures and overcoming physicochemical, pharmaceutical
and biopharmaceutical barriers to a drug's usefulness. Prodrugs can be used for several
reasons e.g. to enhance poor aqueous solubility, permeability or chemical stability, to
prolong the duration of drug action, to improve drug targeting, to reduce side-effects
and too rapid elimination and to extend the patent protection of the parent drug (Stella
1996, Stella 2004, Testa 2004).
Prodrugs are pharmacologically inactive molecules that require an enzymatic and/or
chemical transformation to release an active parent drug in vivo to exert a
pharmacological effect (Figure 2.3) (Stella et al. 1985). The release of the active drug
molecule and the promoiety may occur prior to, during or after absorption or in the
specific target tissue. An ideal prodrug has optimal physicochemical properties, such as
lipophilicity and solubility, it is stable in the GI-tract or in its desired dosage form, the
promoiety is non-toxic and it releases the active drug at an appropriate rate in vivo
(Stella 1996, Stella 2004, Testa 2004).
Drug
Drug Promoiety Drug
Barrier
Enzymatic and/or
chemical transformation
Drug +Promoiety Promoiety
Figure 2.3. The illustration of the prodrug concept (prodrug = drug + promoiety)
The bioactivation mechanism for most prodrug structures is enzymatic or at least
requires enzymes to initialize the bioactivation process, which can then further continue
chemically. More rapid bioactivation has often been achieved by a double prodrug by
linking a short alkyloxy (e.g. methyloxy and ethyloxy) spacer between a promoiety and
parent drug. These spacers are used to enhance the chemical space around the
enzymatically cleavable bond and undergo a spontaneous chemical hydrolysis after the
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enzymatic hydrolysis of the promoiety (Scheme 2.1) (Safadi et al. 1993, Varia, Schuller
and Stella 1984).
XR
R'
O Promoiety XR
R'
OH
XHR
O
R'
Enzymatic
cleavage
Spontaneous
chemical
cleavage
+
Active drug      Aldehyde
- Promoiety
X = O, N, S etc.
R' = H, CH3 etc.
Scheme 2.1. The two-step hydrolysis of alkyloxy-linked prodrugs
One prerequisite for prodrugs is that the promoiety should be nontoxic. However,
there are cases in which a questionable structure provides properties superior to other
structures and thus the risk of the toxic promoiety may be worthwhile. A methyloxy
spacer is an example of a marketed prodrug structure (e.g. fosphenytoin, tenofovir
disoproxil fumarate), where a toxic linker or promoiety is released in the body during
the bioactivation process. This is because the bioconversion of methyloxy linked
prodrugs leads to the liberation of toxic formaldehyde within the body (Heck et al.
1990). Other examples of possible toxicity caused by prodrugs are pivaloyl derivatives
(e.g. adefovir dipivoxil) that release the pivalate-group (trimethylacetic group).
Pivalates have been reported to interfere with carnitine homeostasis in humans (Brass
2002). However, the risk of dose-dependent formaldehyde-mediated toxicity (Slikker et
al. 2004) of prodrugs can be managed by measuring the levels of formaldehyde with
and without the prodrug administration, and the risk of changes in carnitine homeostasis
can be reduced by carnitine supplementation coadministered simultaneously with a
pivalate-generating prodrug (Brass 2002).
2.2.1 Functional group considerations for prodrug derivatization
Prodrug structures for the most common functionalities, such as carboxylic, hydroxyl,
amine, phosphate/phosphonate and carbonyl groups, include esters, carbonates,
carbamates, amides, phosphates and oximes. However, various other, more uncommon,
functional groups have been investigated as potentially useful structures in prodrug
design. Thiols, for example, react in a similar manner as alcohols and can be derivatized
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to thioethers (Majumdar and Sloan 2006) and thioesters (Peyrottes et al. 2004). Amines
may be derivatized into imines (Fozard 2000, Rouleau et al. 1997) and N-Mannich
bases (Simplicio et al. 2007). Some typical prodrug structures for the most common
functionalities are illustrated in Scheme 2.2.
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Scheme 2.2. Functional groups amenable to prodrug design
Ester prodrugs are most often used if one wishes to enhance the lipophilicity, and
thus, the passive membrane permeation of water-soluble drugs by masking charged
groups (e.g. carboxylic acids and phosphates) (Beaumont et al. 2003, Taylor 1996).
Once in the body, the ester bond is readily hydrolyzed by the many esterases
(carboxylesterases, acetylcholinesterases, butyrylcholinesterases, paraoxonases and
arylesterases) found in the blood, liver, and other organs and tissues (Liederer and
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Borchardt 2006). Esters are the most common prodrugs used, and it has been estimated
that approximately 50 % of all marketed prodrugs are activated by hydrolysis (Ettmayer
et al. 2004). There are a number of ester prodrugs in clinical use and they have many
applications (Beaumont et al. 2003). Some representative examples are oseltamivir,
famciclovir, valacyclovir, adefovir dipivoxil, latanoprost, tazarotene and pradefovir and
these are all described more in greater details below with a summary of their uses.
Carbonates and carbamates differ from esters by having an oxygen or nitrogen on
both sides of the carbonyl carbon. Carbonates are carboxylic acid and alcohol
derivatives, and carbamates are carboxylic acid and amine derivatives. Carbonates and
carbamates often are enzymatically more stable than the corresponding esters but more
susceptible to hydrolysis than amides. The bioconversion of many carbonate and
carbamate prodrugs require esterases for the formation of the parent drug (Potter and
Wadkins 2006). Representative examples are tenofovir disoproxil fumarate of the
carbonate prodrugs and irinotecan and cabecitabine of the carbamate prodrugs.
Amides are derivatives of amine and carboxyl functionalities of a molecule. In
prodrug design, amides have been used to only a limited extent due to their relatively
high enzymatical stability in vivo. An amide bond is usually hydrolyzed by ubiquitous
carboxylesterases (Potter and Wadkins 2006), peptidases or proteases (Yang et al.
1999). Amides are often designed for enhanced oral absorption by synthesizing
substrates of some specific intestinal uptake transporter (Steffansen et al. 2004, Yang et
al. 1999). The orally administered amide prodrug, midodrine, is a representative
example of the amide prodrugs.
Phosphate ester prodrugs are typically designed for hydroxyl and amine
functionalities of poorly water-soluble drugs with the intention of enhancing their
aqueous solubility to achieve improved oral and parenteral administration. The
dianionic phosphate promoiety usually clearly elevates the aqueous solubility
(Heimbach et al. 2007, Heimbach et al. 2003). Phosphate prodrugs typically show
reasonable chemical stability and rapid bioconversion back to the parent drug by the
alkaline phosphatases present at the intestinal brush border or in the liver (Heimbach et
al. 2007, Heimbach et al. 2003). Fosphenytoin and phosphonooxymethyl propofol are
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examples of parenteral phosphate prodrugs, and fosamprenavir and estramustine
phosphate are examples of orally active phosphate prodrugs.
 Oximes (ketoximes, amidoximes, and guanidoximes) are derivatives of ketones,
amidines and guanidines, and they thus provide an opportunity to modify molecules that
lack hydroxyl, amine or carboxyl functionalities. Oximes are hydrolyzed by microsomal
cytochrome P450-enzymes (CYP 450) (Jousserandot et al. 1998, Kumpulainen et al.
2006), which are versatile xenobiotic metabolizing enzymes (Guengerich 2001,
Meunier et al. 2004). Oximes, especially strongly basic amidines and guanidoximes,
may be used in enhancing the membrane permeability and absorption of a drug
(Clement 2002). An example of an amidine prodrug is ximelagatran.
2.2.2 Prodrugs for improved oral absorption
2.2.2.1 Improved aqueous solubility
Approximately 40 % of NCEs produced from combinatorial screening programs suffer
from poor aqueous solubility having an aqueous solubility less than 10 mM (Lipinski
2002, 2004). Many of the water-soluble prodrugs for enhanced oral drug delivery
include the addition of an ionizable progroup to the parent compound (such as
phosphate group), but enhanced water-solubility and thus better oral bioavailability may
also be achieved by decreasing the crystal packing or by affecting to the melting point
of the parent drug (Stella and Nti-Addae 2007). Oral phosphate prodrugs are cleaved at
the intestinal brush border by membrane-bound alkaline phosphatase just prior to the
passive absorption of the active drug through the intestinal membrane, thus providing a
great concentrational driving force for absorption in the intestinal lumen (Fleisher et al.
1996, Heimbach et al. 2007). Phosphate esters offer one way to increase the oral
bioavailability of many sparingly water-soluble drugs, but only a few phosphate
prodrugs for oral administration have been marketed to date (Heimbach et al. 2003).
The challenges to the development of oral phosphate prodrug, are related to poor
enzymatic bioconversion (usually the aqueous solubility of the phosphate prodrug is
enhanced to such an extent that passive diffusion through the intestinal membrane is
prevented), the precipitation of the parent drug after enzymatic cleavage in the intestinal
lumen and poor permeability of the parent drug (Heimbach et al. 2003).
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Estramustine phosphate is a phosphate ester prodrug of estramustine (Emcyt®), which
was launched in the mid 1970s for the treatment of prostate carcinoma and is marketed
in both injectable and oral formulations (Bergenheim and Henriksson 1998, Perry and
McTavish 1995). After the dephosphorylation of the water-soluble estramustine
phosphate to estramustine, it is metabolized to its ketone derivative, estromustine
(Scheme 2.3). Further metabolism of estramustine and estromustine produces two active
metabolites, estradiol and estrone. Thus estramustine phosphate has a dual mechanism
of action, i.e. the estramustine and estromustine exert cytotoxic (antimicrotubule)
effects and estradiol and estrone are responsible for antigonadotropic activity
(Bergenheim and Henriksson 1998, Perry and McTavish 1995). After oral
administration, estramustine phosphate is rapidly converted to estramustine in the GI-
tract, and approximately 75 % of the drug is absorbed. The bioconversion of
intravenously administered estramustine phosphate to estramustine is slower with the
half-life of 1.3 hours in plasma (Perry and McTavish 1995).
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Scheme 2.3. The metabolism of estramustine phosphate (Bergenheim and Henriksson
1998, Perry and McTavish 1995)
Another orally administered phosphate ester prodrug is fosamprenavir (Telzir®,
LexivaTM), a phosphate ester of amprenavir (Agenerase®). The ester prodrug shows 10-
fold higher water-solubility and equivalent or higher oral bioavailability compared to
amprenavir, which is marginally water-soluble (0.04 mg/ml) and requires a high dose
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(2400 mg or 16 capsules required per day) (Chapman et al. 2004, Furfine et al. 2004,
Wire et al. 2006). Fosamprenavir is rapidly hydrolyzed by gut epithelial alkaline
phosphatase to amprenavir during absorption with only a minimal concentration of
fosamprenavir reaching the circulation (Chapman et al. 2004, Wire et al. 2006). The
absolute bioavailability of amprenavir after oral administration of fosamprenavir in
humans has not been established, but the maximum plasma concentration of amprenavir
is reached in 1.5-2 hours. A substantial reduction in the capsule size and number has
been achieved (4 capsules daily, 700 mg each) thus enhancing the patient compliance
and decreasing the incidence of side effects  (Wire et al. 2006). Fosamprenavir is also
often coadministered with ritonafir, which inhibits amprenavir metabolism, leading to
the increased plasma amprenavir concentrations (Wire et al. 2006).
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2.2.2.2 Improved lipophilicity
Prodrugs are most frequently applied to mask polar and ionizable groups of a drug
molecule with the aim to improve the membrane permeability and oral absorption.
Oseltamivir (Tamiflu®) is an orally active prodrug of oseltamivir carboxylate (GS4071,
Ro 64-0802), a selective inhibitor of viral neuramidase glycoprotein of influenza A and
B (Bardsley-Elliot and Noble 1999, Doucette and Aoki 2001, McClellan and Perry
2001) and it has been proposed to have antiviral activity also against avian H5N1 virus,
the virus responsible for the bird flu (O'Malley 2006). As an ethyl ester, oseltamivir is
rapidly and well absorbed from the GI-tract and it increases the oral bioavailability of
oseltamivir carboxylate from 5 % to 79 % (McClellan and Perry 2001, Shi et al. 2006).
Oseltamivir undergoes rapid bioconversion to oseltamivir carboxylate mostly by human
carboxylesterase 1 and the maximum plasma concentration of oseltamivir carboxylate is
reached within 3 to 4 hours after oral administration of oseltamivir (elimination half-life
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= 6-10 hours) (Bardsley-Elliot and Noble 1999, Massarella et al. 2000, Schmidt 2004,
Shi et al. 2006).
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Famciclovir (Famvir®) is an oral diester prodrug of penciclovir, an antiviral agent
used against herpes simplex viruses, type 1 (HSV 1) and type 2 (HSV 2) and varicella
zoster virus (VZV) (Simpson and Lyseng-Williamson 2006). The bioconversion of
famciclovir to penciclovir is two-pronged and requires two enzymes: the acetyl groups
are first hydrolyzed by esterases followed by 6-oxidation of the purine ring by xanthine
or aldehyde oxidases (De Clercq and Field 2006, Harnden et al. 1989, Rashidi et al.
1997). The bioconversion takes places mostly in the liver after rapid absorption of the
prodrug from the GI-tract (Hodge et al. 1989, Simpson and Lyseng-Williamson 2006),
though hydrolysis of one of the ester groups may occur to some extent also in the
intestine before or during absorption (Hodge et al. 1989). After the hydrolysis of both
ester groups, 6-deoxypenciclovir is oxidized to penciclovir by aldehyde oxidase
(Scheme 2.4) (Rashidi et al. 1997). The poor bioavailability of penciclovir is enhanced
up to 77 % and the maximum plasma concentration of penciclovir is achieved within
0.75 hours after oral administration of famciclovir (Hodge et al. 1989, Simpson and
Lyseng-Williamson 2006).
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Scheme 2.4. The bioactivation of famciclovir to penciclovir (Rashidi et al. 1997)
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Adefovir dipivoxil (Hepsera®) is an orally active diester prodrug of adefovir, a
nucleoside reverse transcriptase inhibitor against hepatitis B virus (Noble and Goa
1999). Pivaloyloxymethyl promoiety is attached to both hydroxyl groups of the
phosphonate group of adefovir, which enhances its lipophilicity sufficiently to allow
passive oral absorption (Dando and Plosker 2003, Noble and Goa 1999). Ester groups of
adefovir dipivoxil are cleaved by hepatic extracellular esterases, following the rapid
chemical hydrolysis of oxymethyl groups to free phosphonate (Scheme 2.5). Further
phosphorylation to the active monophosphate is catalyzed by cellular adenylate kinases
(Dando and Plosker 2003, Noble and Goa 1999). Absorption of adefovir dipivoxil is
rapid and the maximum plasma concentration of adefovir is reached within 0.75 hours
after oral administration of adefovir dipivoxil with oral bioavailability of 59 %
(elimination half-life = 6-7 hours) (Dando and Plosker 2003, Sun et al. 2007).
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Scheme 2.5. The enzymatical and chemical bioactivation of adefovir dipivoxil
Tenofovir disoproxil fumarate (Viread®) is a carbonate prodrug of tenofovir, a
nucleotide transcriptase inhibitor against HIV (Chapman et al. 2003) and hepatitis B
virus (van Bommel et al. 2006). Diisopropyl carbonate groups are attached to both
hydroxyl functionalities of tenofovir phosphonate group via an oxymethyl spacer to
enhance the lipophilicity, and thus, to improve the oral bioavailability of tenofovir. The
carbonate structure was found to be chemically more stable compared to the
corresponding esters and the prodrug is rapidly converted to tenofovir in the liver by
esterases and subsequently phoshorylated by cellular enzymes to form tenofovir
diphosphate (Shaw et al. 1997, van Gelder et al. 2002). The enzymatic reaction
followed with rapid spontaneous cleavage of formaldehyde is similar to that of adefovir
dipivoxil. The bioavailability of tenofovir after oral administration of tenofovir
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disoproxil fumarate is 25 % and the maximum plasma concentration of tenofovir is
reached within 2.3 hours (Chapman et al. 2003, Lyseng-Williamson et al. 2005).
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A more recent example of an ethyl ester prodrug is ximelagatran (Exanta®), a prodrug
of melagatran, which is the first member of orally administered direct thrombin
inhibitors (Eriksson et al. 2003). As a zwitterion, melagatran has poor oral
bioavailability, only 3-7 %. Ximelagatran is a double prodrug, as in addition to an ethyl
ester group in the carboxylic acid end, it contains an N-hydroxyamidine group in the
amidine end of melagatran. Therefore, the formation of melagatran requires two
metabolic reactions. The N-hydroxy group is reduced to an amidine in the liver, and to
some extent also in the intestine, by CYP-enzymes. The ethyl ester is then hydrolyzed
to free carboxylic acid in the liver by carboxyl esterases (Clement and Lopian 2003,
Eriksson et al. 2003). The poor oral bioavailability of melagatran is improved to 20 %
by using ximelagatran and the maximum plasma concentration of melagatran is reached
within 1.9 hours (Eriksson et al. 2003). Ximelagatran was marketed between 2003-2004
in the US and in Europe as the first oral treatment categorized under the World Health
Organization class of direct thrombin inhibitors. However, in February 2006, it was
withdrawn from the market after an extended clinical trial confirmed the initial concerns
that it caused severe liver toxicity (Frantz 2007).
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2.2.2.3 Carrier-mediated absorption
Recent progress in molecular biology has allowed the identification and cloning of
nutrient transporters. Prodrugs targeted towards specific membrane transporters are
designed to have structural features that mimic the natural substrates of the endogenous
uptake transporters present on the intestinal epithelium (Han and Amidon 2000,
Majumdar et al. 2004, Sai and Tsuji 2004, Yang et al. 1999). Targeting specific
transporters is particularly important for drugs that are either so polar or so charged that
they have negligible passive absorption.
Peptide transporters appear to be attractive targets in prodrug design, as they are
widely distributed throughout the small intestine and show sufficiently high transport
capacity and broad substrate specificity (Han and Amidon 2000, Steffansen et al. 2004,
Yang et al. 2001). Valacyclovir (Valtrex®) is a representative example of a prodrug that
exploits carrier-mediated transport. Valacyclovir is an oral L-valine amino acid ester
prodrug of acyclovir, an antiviral agent used against herpes zoster virus (Acosta and
Fletcher 1997, Ormrod and Goa 2000, Wu et al. 2003). Valacyclovir is a substrate of
human intestinal peptide transporter (hPEPT1) (Balimane et al. 1998, de Vrueh et al.
1998, Guo et al. 1999), and it is rapidly transported across the intestinal membranes.
Bioconversion of valacyclovir to acyclovir by valacyclovir hydrolase (VACVase) is
efficient as over 99 % of valacyclovir is converted to acyclovir (Kim et al. 2003,
Ormrod and Goa 2000). The bioavailability of acyclovir after oral administration of
valacyclovir is enhanced from 20 % to 54 % with the tmax of approximately 2 hours
(Acosta and Fletcher 1997, Ormrod and Goa 2000).
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Midodrine (ProAmatine®) is an oral prodrug of desglymidodrine (DMAE), a selective
?1-adrenoceptor agonist for the treatment of orthostatic hypotension (Tsuda et al. 2006).
The glycine promoiety is attached to the amine functionality of DMAE and the prodrug
is converted into its active drug DMAE, mainly in the liver and in the systemic
circulation by unknown peptidases (Cruz 2000). Midodrine is a substrate of the H+-
coupled human peptide transporter 1 (hPEPT 1) expressed in the intestinal epithelial
cells and this active carrier-mediated transport system elevates the bioavailability of
midodrine to 93 % compared to only 50 % for DMAE (Cruz 2000, Tsuda et al. 2006).
DMAE crosses the BBB poorly and thus it exerts some unnecessary effects on the
central nervous system. The maximum plasma level of DMAE after oral administration
of midodrine is reached in 1-2 hours and it has a t1/2 of approximately 25 minutes
(Stewart 2006).
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2.2.3 Prodrugs for improved intravenous administration
While examples of marketed water-soluble oral prodrugs are rare, there are several
successful prodrugs with improved solubility properties for i.v. administration. The
most commonly used approach to increase the water-solubility by prodrugs is to
introduce an ionizable/polar promoiety into the parent drug. A number of phosphate
esters have been developed as potential water-soluble prodrugs for i.v. administration
and less commonly for oral administration.
Fosphenytoin (Cerebyx®) is a phosphate ester prodrug of poorly water-soluble
phenytoin for the acute treatment of seizures, and can be used for either i.v. or
intramuscular administration (Boucher 1996, Browne et al. 1996). In fosphenytoin, a
phosphate ester is attached to the weakly acidic (pKa = 8.3) amine functionality of
phenytoin via the oxymethyl spacer group leading to a remarkable increase in its
aqueous solubility (from 20-25 ?g/ml of phenytoin to 140 mg/ml of fosphenytoin)
(Varia, Schuller, Sloan et al. 1984). Following i.v. administration, fosphenytoin is
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completely converted back to phenytoin by hepatic alkaline phosphatases, with half-
lives ranging from 7 to 15 minutes in patients (Browne et al. 1996, Varia, Schuller,
Sloan et al. 1984). The recovery of phenytoin is almost quantitative with only 1-5 % of
the fosphenytoin dose being recovered in urine. Thus, the bioavailability of
fosphenytoin is almost 100 % and comparable with that of the intravenously delivered
phenytoin (Boucher 1996). After intramuscular administration, the maximum plasma
concentration of phenytoin is reached within 2-4 hours (Fischer et al. 2003).
Fosphenytoin has been reported to be safer than phenytoin in terms of its ability to
evoke cardiac toxicity (DeToledo and Ramsay 2000, Ramsay and DeToledo 1996), but
recent studies have indicated that the occurence of these side effects may be more
common than previously thought (Adams et al. 2006).
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Irinotecan (CPT-11, Camptosar®) is a parenteral water-soluble carbamate prodrug of a
lipophilic antineoplastic topoisomerase I inhibitor, camptothecin (SN-38) which is used
in the treatment of recurrent, metastatic colorectal cancer. It represents an ionizable
promoiety to improve the aqueous solubility (Bencharit et al. 2002, Rothenberg 2001,
Sanghani et al. 2004, Slatter et al. 1997). In the irinotecan molecule, a dipiperidino
promoiety is attached to the phenol moiety of camptothecin via a carbamate bond. The
bioconversion back to camptothecin occurs primarily in the liver, and to a minor extent
inside the tumors (Guichard et al. 1999), by human carboxylesterases (Sanghani et al.
2004). Both irinotecan and camptothecin exist in pH-dependent equilibrium between
lactone and carboxylate forms, of which the lactone is the pharmacologically active
form (Slatter et al. 2000). The bioconversion of CPT-11 to camptothecin is not very
effective, as only 10 % of CPT-11 is converted to camptothecin with an elimination
half-life (t1/2) of approximately 14 hours (Rivory et al. 1997). In addition, the intestinal
bioconversion of the prodrug to the cytotoxic drug leads to severe diarrhoea after the
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treatment and limits its use. Thus recent studies have focused more on finding tumor-
sensitive bioconversion mechanisms of CPT-11 by exploiting hypoxia- and transgene-
mediated over-expression of the carboxylesterases in tumors (Matzow et al. 2007).
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2.2.4 Prodrugs for improved topical administration
Topical administration of drugs encompasses all external membranes, though ocular and
dermal drug delivery are the most widely used forms of topical prodrug applications.
The unfavourable physicochemical properties of many drug molecules lead to poor
permeation across the stratum corneum of the skin or the corneal barrier of the
intraocular tissues (Brown et al. 2006, Urtti 2006). These features can often be achieved
by the prodrug approach (Fang and Leu 2006, Järvinen and Järvinen 1996, Sloan and
Wasdo 2003).
A prostaglandin analog latanoprost (Xalatan®) represents a new class of active ocular
hypotensive agents for the treatment of glaucoma. It is a lipophilic isopropyl ester
prodrug that is rapidly hydrolyzed inside the ocular tissue to biologically active
prostaglandins. In its carboxylic acid form, the active drug is poorly permeable and
causes irritation while the lipophilic prodrug achieves improved ocular absorption and
better safety (Hellberg et al. 2003, Netland et al. 2001, Sharif et al. 2003, Susanna et al.
2002).
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Latanoprost has been shown to be more effective when compared to the traditionally
used ?-adrenergic receptor antagonist timolol in reducing intraocular pressure (Chew et
al. 2004, Harasymowycz et al. 2007); it enables once-daily dosing and maintains
efficacy even after long-term use and causes no severe systemic and ocular side effects
(Thelen et al. 2007). The reduced systemic side-effects are a result of the lowered
concentrations of latanoprost in the systemic circulation and rapid elimination of
latanoprost in the plasma (t1/2 = 17 minutes) (Alm 1998).
Tazarotene (Tazorac®) is a lipophilic ethyl ester of tazarotenic acid used for the
treatment of psoriasis and acne (Dando and Wellington 2005, Guenther 2003). It is
rapidly converted to an active drug after percutaneous absorption by esterases and only
5 % of tazarotene is systemically absorbed (Foster et al. 1998). Since it masks the free
carboxylic acid functionality of tazarotenic acid, it evokes less skin irritation (Marks
1997). There is very little systemic absorption of tazarotene because of its limited
percutaneous penetration. Principally due to the short systemic half-life and less
extensive lipophilicity of the released tazarotenic acid, this compound displayed no
accumulation in adipose tissues (Tang-Liu et al. 1999). Tazarotene is rapidly
metabolized to tazarotenic acid and to its metabolites (sulfoxide and sulfone) in the skin
and the plasma, thus resulting in minimal systemic adverse effects (Chandraratna 1996,
Dando and Wellington 2005, Marks 1998). Thus, tazarotene is not only a carboxylic
acid prodrug with enhanced skin permeability, but it also acts as a soft-drug with
enhanced systemic metabolism. Soft-drugs, unlike prodrugs, are active drugs that are
designed to undergo a predictable and controllable deactivation or metabolism in vivo
after achieving their therapeutic effect (Bodor and Buchwald 1997, 2000, Thorsteinsson
et al. 2003). In addition, much smaller doses of topically administered tazarotene are
required compared to oral retinoids and the drug is delivered directly into the target skin
tissues (Tang-Liu et al. 1999).
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2.2.5 Prodrugs for site-selective drug delivery
Site-selective drug delivery is the ultimate goal in drug therapy. Site-selectivity may be
achieved by passive drug enrichment in the organ, via transporter mediated delivery, by
selective metabolic activation through enzymes, and by antigen targeting (Ettmayer et
al. 2004, Petrak 2005). Some examples of the more widely studied applications, e.g.
CNS-, tumor- and liver-targeting are discussed in more detail below.
2.2.5.1 CNS-targeted drug delivery
As described in chapter 2.1.1.2, the BBB is a challenge to the transport of drugs to the
CNS. A traditional approach to increase the drug concentration in CNS has been to
increase of the lipophilicity of the parent drug. This passive enrichment requires the
prodrug to have ready access to the brain tissue, the site-selective bioconversion of the
prodrug back to the parent drug and the prolonged retention of the parent drug within
the brain tissue (de Boer and Gaillard 2007, Siegal and Zylber-Katz 2002). Once the
lipophilicity of the drug is increased via a prodrug, the prodrug will exhibit improved
penetration into the CNS. Increased lipophilicity alone, however, does not ensure that a
higher concentration of parent drug will be presented in the target tissue. The target
tissue bioconversion needs to be rapid and selective enough to compete with the
elimination from the target tissue, and also to ensure that the premature bioconversion
of the prodrug is sufficiently low. By understanding the specific transport mechanisms
and enzymatic activity at the CNS and BBB, it is often possible to achieve substantially
enhanced CNS delivery and to prevent possible adverse effects in other organs / tissues
(Anderson 1996, de Boer and Gaillard 2007).
Levodopa (Dopar®) can be considered as a prodrug which achieves targeted delivery
into central dopaminergic neurones. Levodopa is a substrate for the neutral amino acid
transporter (LAT1) expressed at the BBB (Sampaio-Maia et al. 2001). This uptake
transporter carries levodopa to the brain tissue, where levopoda is rapidly converted to
dopamine by enzymes only present in nerves (Scheme 2.6). After the bioconversion, a
very hydrophilic dopamine is trapped into the CNS, enabling its pharmacodynamic
effects selectively in brain tissue (Nutt and Woodward 1986, Nutt et al. 1984).
Levodopa is usually administered along with peripheral dopa-decarboxylase inhibitors
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(DCI), such as carbidopa or benserazide. Thus the peripheral decarboxylation to
dopamine, norepinephrine, and epinephrine by dopa-decarboxylase can be avoided
leading to diminished risk of undesired cardiovascular and gastrointestinal side effects
(Kadieva et al. 2005, Lledó 2001).
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Scheme 2.6. The bioconversion of levodopa to dopamine
2.2.5.2 Tumor-targeted drug delivery
The aim of cancer therapy is to target an inactive prodrug selectively to tumor cells,
where the active drug is released without being toxic to normal, healthy tissue (Aisner
2007, de Groot et al. 2001). Due to the high proliferation rates of tumor cells, in
addition to the bioreductive activity, certain enzyme levels are often elevated in these
cells and this property has been exploited in targeted prodrug-tumor delivery (Aisner
2007). The development pipelines of the pharmaceutical companies also reflect the
importance and benefits of targeting of antitumor agents, i.e. in 2006 half of the total
380 oncology products in late-stage development were targeted therapies (Longwell
2007).
Capecitabine (Xeloda®) is an orally administered carbamate prodrug of 5-FU,
requiring a cascade of three enzymes for its bioconversion to the active drug.
Capecitabine is absorbed intact from the intestine and undergoes the final step of the
bioconversion pathway within the tumors, thus avoiding systemic toxicity (Doyle and
Engelking 2007, Walko and Lindley 2005). The enzymatic bioconversion pathway is
initiated in the liver, where human carboxylesterases 1 and 2 cleave the ester bond of
the carbamate (Scheme 2.7) (Quinney et al. 2005). This is followed by a rapid,
spontaneous decarboxylation reaction resulting in the formation of 5'-deoxy-5-
fluorocytidine (5'-dFCyd) (Walko and Lindley 2005). The reaction continues in the
liver, and to some extent in tumors, by cytidine deaminase which converts 5'-dFCyd to
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5'-deoxyuridine (5'-dFUrd). The final activation step takes place in the tumors, where
thymidine phosphorylase (dThdPase) liberates the active drug 5-FU (Miwa et al. 1998,
Walko and Lindley 2005). The bioavailability of 5-fluorouracil after oral administration
of cabecitabine is almost 100 % (Doyle and Engelking 2007, Walko and Lindley 2005)
and the safety profile of cabecitabine is much more favorable compared to that of
intravenous 5-fluorouracil (Cassidy et al. 2002).
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Scheme 2.7. The bioconversion of cabecitabine to 5-fluorouracil (Miwa et al. 1998,
Walko and Lindley 2005).
To expand the range of tumors susceptible to enzyme-prodrug cancer therapy,
prodrug-activating exogenous enzymes can be delivered to tumor cells by using
antibodies and genes. The most common approaches are antibody-directed enzyme
prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT).
ADEPT is a two-step therapy, in which the enzyme-antibody conjugate first binds to a
tumor-specific antigen on the malignant cell membrane (Bagshawe et al. 2004, Damen
et al. 2001, de Groot et al. 2001, Sharma et al. 2005). The inactive prodrug is then
administered and activated to an active cytotoxic drug by the localized enzyme. The
principle of GDEPT is similar, but the enzyme is localized within tumor cells using a
targeting vector to deliver the gene encoding the enzyme into the tumor cells (Dachs et
al. 2005, Niculescu-Duvaz et al. 1998). While few ADEPT systems have so far
progressed to the clinical phase I studies (Chester et al. 2004, Francis et al. 2002,
Napier et al. 2000), one GDEPT has reached multicenter phase III clinical trials (Dachs
et al. 2005).
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2.2.5.3 Liver-targeted drug delivery
Since the liver is the most important metabolizing organ, it possesses a wide variety of
liver-specific metabolizing enzymes capable of prodrug activation (van Montfoort et al.
2003). Pradefovir mesylate is a cyclic 1,3-propanyl ester prodrug of a nucleoside
monophosphate (NMP), adefovir, which is being tested for the use in the treatment of
hepatitis B (Erion et al. 2006, Erion et al. 2004). Pradefovir undergoes a cytochrome
P450 (CYP) 3A4 catalyzed oxidation predominantly in liver hepatocytes (Erion et al.
2004, Lin et al. 2006). The oxidation results in ring opening and ?-elimination of an
aryl vinyl ketone. The released monophosphate adefovir is further converted by
nucleotide kinases to the active nucleoside triphosphate (NTP) (Erion et al. 2004). In
phase II clinical trials in hepatitis B patients, pradefovir has demonstrated good efficacy
with low systemic adefovir levels, which is indirect evidence for liver targeting (Erion
et al. 2006).
P O
O
Cl
O
N
N N
N
NH2
O
Pradefovir
2.2.6 Prodrugs for prolonged duration of drug action
Although various pharmaceutical formulations are frequently used to prolong the
duration of drug action, there are a few examples where prodrugs have been used for
this purpose. Very lipophilic prodrugs of several steroids (e.g. testosterone nandrolone)
and neuroleptics (e.g. fluphenazine, flupenthixol, haloperidol) are slowly released from
the site of intramuscular injection and result in a prolonged duration of action (Altamura
et al. 2003, Minto et al. 1997). Once released from the injection site, the prodrugs are
usually rapidly bioconverted, in most cases with no attenuation of their therapeutic
action. As an example, the onset of action of fluphenazine generally appears between 24
to 72 hours after injection of its lipophilic decanoate ester prodrug, and thus gradual
release continues for 1 to 8 weeks with an average duration of 3 to 4 weeks (Marder et
al. 2002).
Bambuterol (Bambec®, Oxeol®) is a biscarbamate ester prodrug of the beta2-agonist
terbutaline for use in the treatment of asthma. It is slowly bioconverted to terbutaline
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predominantly outside the lungs via hydrolysis by butyrylcholinesterases and oxidation
reactions to products which can further be hydrolysed to terbutaline (Sitar 1996,
Svensson 1987, 1991). Bambuterol is stable to presystemic elimination and is
concentrated by lung tissue after absorption from the GI tract. The maximum plasma
concentrations of terbutaline after bambuterol administration occur approximately at 4
to 7 hours and the efficacy of bambuterol has been shown to last for 24 hours (Sitar
1996). As a result of its prolonged duration of action, once-daily bambuterol treatment
provides relief of asthma with a lower incidence of side-effects than terbutaline which
has to be taken three times a day (Persson et al. 1995).
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3 AIMS OF THE STUDY
The general objective of the present study was to design, synthesize and evaluate novel
prodrug structures, which could improve the physicochemical, pharmaceutical or
biopharmaceutical properties of drug molecules. The model compounds used in this
study were nabumetone, ketoprofen and propofol. The specific aims were:
1. To synthesize and fundamentally characterize the usefulness of the
hydroxyimine as a prodrug structure of a ketone drug in vitro and in vivo.
2. To develop a synthesis route for 1-chloroethyl phosphates and to evaluate their
usefulness as building blocks of ethylidene linked prodrug structures.
3. To synthesize an ethylidene linked phosphate prodrug of propofol and to
evaluate its usefulness as a prodrug structure for improved aqueous solubility in
vitro and in vivo.
4. To synthesize monomethyl phosphate esters of propofol and to evaluate their
usefulness as biodegradable prodrug structures with improved membrane
permeation abilities in vitro and in vivo.
66
4 GENERAL EXPERIMENTAL PROCEDURES
4.1 General synthetic procedures
This chapter describes the general synthetic procedures of the compounds evaluated in
this thesis. Detailed descriptions of the synthesis procedures are given in chapters 5-8.
All reagents obtained from commercial suppliers were used without further purification.
The described reactions were monitored by thin-layer chromatography using aluminum
sheets precoated with Merck silica gel 60 F254. Samples were visualized by UV-light and
staining using anisaldehyde, KMnO4 or ninhydrine. Column chromatography was
performed with silica gel (0.063-0.200 mm mesh). 1H, 13C and 31P NMR spectra were
recorded at 500.13, 125.78 and 200.46 MHz at 25ºC, respectively. TMS or TSP was used
as an internal reference for 1H and 13C measurements and H3PO4 as an external reference
for 31P measurements. The splitting pattern abbreviations are as follows: s = singlet, d =
doublet, t = triplet, q = quartet, sep = septet, m = multiplet. Electron impact or positive
chemical ionization mass spectra were acquired by an Agilent Technologies gas
chromatograph- mass spectrometry system (part numbers 6890N G 1530N and 5973 G
2589A). Electronspray ionization mass spectra were acquired by an LCQ quadrupole ion
trap mass spectrometer with an electronspray ionization source (Finnigan MAT, San Jose,
CA). Elemental analyses were carried out on a ThermoQuest CE Instruments EA 1110-
CHNS-O elemental analyzer.
4.2 Determination of the aqueous solubility
The aqueous solubilities were determined at room temperature in an appropriate buffer
solution (0.16 M phosphate buffer or 0.05 mM Tris-HCl-buffer at pH 7.4, 0.05 M acetate
buffer at pH 5.0). The pH of the mixtures was held constant during the study. Excess
amounts or a known amount (due to the small amount of compound available) of each
component were added to 1 or 0.5 ml of buffer solution and the mixtures were stirred at
room temperature for 48 hours or less, filtered (0.45 ?m Millipore) and analyzed by
HPLC.
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4.3 Determination of the distribution coefficient
The distribution coefficients (log D) were determined at room temperature with a 1-
octanol- aqueous buffer system at pH 7.4 and at pH 5.0 (0.16 M phosphate buffer or
0.05 mM Tris-HCl-buffer at pH 7.4, 0.05 M acetate buffer at pH 5.0). Before use, the 1-
octanol was saturated with buffer by stirring vigorously for 24 h. A known
concentration of each compound was dissolved in buffer and pH was adjusted to either
7.4 or 5.0. The solution was shaken with a suitable volume of 1-octanol for 60 min.
After shaking, the phases were separated by centrifugation at 10 000 rpm for 10 min.
The concentrations of the compounds in the buffer phase before and after the
partitioning were determined by HPLC.
4.4 Determination of the chemical stability
The rate of the chemical degradation was determined at 37ºC in an appropriate buffer
(0.16 M phosphate buffer, 0.05 mM Tris-HCl-buffer or 0.18 M borate buffer at pH 7.4,
0.05 M acetate buffer at pH 5.0). An appropriate amount of compound was dissolved in
preheated buffer solution and the solutions were placed in a thermostatically controlled
water bath at 37ºC. Samples were taken at predetermined time intervals and analyzed by
HPLC. Pseudo-first-order half-lives (t1/2) for the degradation of prodrugs were
calculated from the slope of the linear portion of the plotted logarithm of remaining
prodrug versus time.
4.5 Determination of the degradation in human serum
The rate of enzymatic degradation of prodrugs was determined in human serum at 37°C.
One volume of 100 µM solution of prodrug in 0.05 mM phosphate buffer (pH 7.4) was
diluted with four volumes of preheated human serum and vortex mixed. The solutions
were kept in an incubator at 37°C and 200 µl aliquots of serum/buffer solution were
taken at appropriate time intervals followed by addition of 200 µl of ice-cold
acetonitrile to precipitate protein from serum. After immediate mixing and
centrifugation for 15 min at 11000 rpm, the supernatant was analyzed for remaining
prodrug and released parent drug by the HPLC. Pseudo-first-order half-life (t1/2) for the
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degradation of prodrug was calculated from the slope of the linear portion of the plotted
logarithm of the remaining prodrug versus time.
4.6 Determination of the enzymatic hydrolysis in alkaline phosphatase or in
phosphodiesterase  solution
The unit amounts of alkaline phosphatase type VII-S from bovine intestinal mucosa and
phosphodiesterase I from Western Diamondback Rattlesnake venom (Crotalux atrox)
were used as defined by a supplier (Sigma-Aldrich). An appropriate amount of prodrug
(final concentration typically 50 µM) was dissolved in preheated buffer solution (pH
7.4) and the solutions were placed in a thermostatically controlled water bath at 37ºC.
The enzymatic reaction was started by adding enzyme to the solution. In blank
solutions, enzyme was replaced with the same volume of water to ensure that the
hydrolysis was clearly enzymatic. At predetermined time intervals, 200 µl samples were
removed and 200 µl ice-cold acetonitrile was added to each sample to stop the
enzymatic hydrolysis. The samples were kept on ice, centrifuged for 10 min at 14000
rpm, and the supernatant was analyzed by the HPLC. Pseudo-first-order half-lives (t1/2)
for the hydrolysis of prodrugs were calculated from the slope of the linear portion of the
plotted logarithm of the remaining prodrug versus time.
4.7 Determination of the enzymatic hydrolysis in rat liver homogenate
The 20 % rat liver homogenate was prepared by homogenizing rat liver with four
equivalents of isotonic 50 mM Tris-HCl buffer (pH 7.4). The homogenate was
centrifuged for 90 min at 9000 × g and the supernatant was stored at -80 ºC before use.
One volume of prodrug solution in 50 mM Tris-HCl buffer (pH 7.4, 37°C, final
concentration typically 100 µM) was added into one volume of rat liver homogenate. In
blank solutions, liver homogenate was replaced with the same volume of water to
ensure that the hydrolysis was clearly enzymatic. At predetermined time intervals, 150
µl samples were removed and 150 µl ice-cold acetonitrile was added to each sample to
stop the enzymatic hydrolysis. The samples were kept on ice, centrifuged for 10 min at
14000 rpm, and the supernatant was analyzed by the HPLC. Pseudo-first-order half-
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lives (t1/2) for the hydrolysis of prodrugs were calculated from the slope of the linear
portion of the plotted logarithm of the remaining prodrug versus time.
4.8 Animal treatments
Adult male Wistar rats weighing approximately 250 g were used in all animal studies and
were purchased from the National Laboratory Animal Centre (Kuopio, Finland). Rats
were housed on a 12 hours light/dark cycle. All experiments were carried out during the
light phase. The rats had free access to tap water and food pellets. All procedures were
reviewed and approved by the Animal Ethics Committee at the University of Kuopio.
Detailed experimental procedures are described in chapters 5, 7 and 8.
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5 EVALUATION OF HYDROXYIMINE AS CYTOCHROME P450-SELECTIVE
PRODRUG STRUCTURE*
Abstract: Hydroxyimine derivatives of ketoprofen (1) and nabumetone (2) were
synthesized and evaluated in vitro and in vivo as cytochrome P450-selective intermediate
prodrug structures of ketones. While 1 released ketoprofen extremely slowly in vitro, 2
released nabumetone at an appropriate rate in vitro in the presence of isolated rat and
human liver microsomes and different recombinant human CYP isoforms. Bioconversion
of 2 to both nabumetone and its active metabolite, 6-methoxy-2-naphtylacetic acid (6-
MNA), was further confirmed in rats in vivo. Results indicate that hydroxyimine is a
useful intermediate prodrug structure for ketone drugs.
* Adapted with permission from: Kumpulainen H,# Mähönen N,# Laitinen M-L,
Jaurakkajärvi M, Raunio, H, Juvonen, R, Vepsäläinen, J, Järvinen, T, Rautio J.
Evaluation of hydroxyimine as Cytochrome P450-Selective Prodrug Structure: Journal
of Medicinal Chemistry 49: 1207-11, 2006. Copyright 2007 American Chemical
Society. # Authors contributed equally to this work
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5.1 Introduction
Prodrug structures have mainly been developed for amine, hydroxyl and carboxyl
functionalities of drug molecules (Fleisher et al. 1996). Only a few prodrug structures
have been developed for molecules containing ketone functionality, although ketone
group is a common functional group in drug molecules. One promising strategy to apply
prodrug approach to a ketone compound is to synthesize an oxime structure via a
hydroxyimine, which is oxidized to the corresponding ketone by microsomal cytochrome
P450 (CYP) enzymes (Jousserandot et al. 1998). CYP enzymes are versatile xenobiotic
metabolizing enzymes (Meunier et al. 2004) and particularly abundant in the liver and
intestinal tract, although they are expressed practically in every tissue of the body (Ding
and Kaminsky 2003). This wide substrate specificity of CYP enzymes can be exploited in
prodrug technology. CYP enzyme mediated reactions have been utilized in targeting
drugs into the liver (Erion et al. 2005), in CYP based gene therapy (Baldwin et al. 2003)
and in activating a prodrug to an active drug during first-pass metabolism in the liver
(Ikeda et al. 2000).
In the prodrug approach, hydroxyimine is especially suitable as an intermediate
structure since it can be further derivatized, for example, to an ester, phosphate or
carbamate. Thus, oxime prodrugs are actually double-prodrugs requiring a two-step
bioactivation process (Scheme 5.1). The oxime structure is first hydrolyzed enzymatically
to hydroxyimine, which is further oxidized to the corresponding active ketone drug by
CYP enzymes. The bioconversion of hydroxyimines to corresponding ketones also leads
to the liberation of nitric oxide (NO) in biological systems (Jousserandot et al. 1995,
Jousserandot et al. 1998, Mansuy et al. 1995, Shaik et al. 2005). Because the CYP
catalyzed oxidation reaction of hydroxyimine occurs in vivo mainly in liver, oximes can
be used to improve site-specificity, especially liver-targeting, of a parent drug. Previously
hydroxyimine structure has been used in a very few prodrug molecules (Mäntylä et al.
2004, Prokai et al. 1995, Venhuis et al. 2003) and their fundamental in vitro/in vivo-
characterization has been lacking.
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Scheme 5.1. The two-step process of the synthesis of an oxime prodrug and enzymatic
activation of an oxime prodrug to the corresponding ketone.
To evaluate the in vitro and in vivo usefulness of the hydroxyimine moiety as an
intermediate prodrug structure for ketones, hydroxyimine derivatives of ketoprofen and
nabumetone, were synthesized. These the ketone functionality containing compounds
were chosen as model compounds because of their suitable detection properties and their
low quantity of other functional groups. In addition, ketoprofen and nabumetone are both
non-steroidal anti-inflammatory drugs (NSAID) and the hydroxyimine can act as a NO-
donating group. Some NSAIDs, e.g. aspirin, naproxen and diclofenac have been coupled
to a NO-donating moiety which may have either protective (e.g. GI-sparing effect or
protective role in some liver injuries) (Whittle 2004) or harmful effects (in conditions
such as liver ischemia (Chen et al. 2003), asthma (Barnes 1995) or rheumatoid arthritis
(van't Hof et al. 2000)) in the body. In this study, these two hydroxyimine intermediate
prodrug structures are extensively characterized with respect to their physicochemical
properties, chemical and enzymatic stability, formation of nitric oxide from the
hydroxyimine structure and the release of their representative parent drug in vitro and in
vivo.
5.2 Results and Discussion
Synthesis. The syntheses of ketoprofen and nabumetone hydroxyimines (1 and 2,
respectively) were obtained in good yields by treating the parent drugs, ketoprofen and
nabumetone with hydroxylamine hydrochloride in the presence of pyridine (Scheme 5.2).
The E- and Z-isomers of 2 could be isolated by column chromatography. However, all the
studies described below were carried out by using the mixture of E- and Z-isomers.
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Scheme 5.2. Reagents a) NH2OH*HCl, Pyr, dioxane, 75 %, b) NH2OH*HCl, Pyr, EtOH,
94 %
Aqueous solubility and lipophilicity. Since hydroxyimines are designed to be
intermediate structures, not final prodrugs, and will be further derivatized, it may be
desired that their physicochemical properties do not differ much from parent molecules.
However, it is important to find out the effects of hydroxyimine structure on
physicochemical properties of a parent drug. Therefore, the aqueous solubilities and
distribution coefficients (log D) of 1 and 2 and their parent compounds at pH 7.4 and 5.0
were determined (Table 5.1). The aqueous solubilities of both hydroxyimines were lower
than their parent compounds at pH 7.4. At pH 5.0 the hydroxyimine structure enhanced
the aqueous solubility of ketoprofen but diminished the aqueous solubility of
nabumetone. The distribution coefficients of 1 and 2 were similar compared to their
parent compounds at both pH 7.4 and 5.0. In conclusion, the differences in aqueous
solubility and lipophilicity between both 1 and 2 compared to their parent drugs were not
significant.
Table 5.1. Aqueous solubilities and distribution coefficients (log D) of ketoprofen,
nabumetone and their hydroxyimines (1, 2) in buffer solutions (mean ± SD, n = 3 unless
otherwise mentioned)
Aqueous solubility (?g/ml) log D
Compd pH 5.0  pH 7.4 pH 5.0  pH 7.4
Ketoprofen  740 ± 30 mg/ml 465 ± 76 mg/ml 2.1 ± 0.01 0.008 ± 0.02
1 1800 ± 300 mg/ml 116 ± 9.2 mg/ml n=2 2.0 ± 0.01  -0.04 ± 0.01
Nabumetone 6.4 ± 0.2 4.3 ± 0.4 3.2 ± 0.04 3.3 ± 0.04
2 3.0 ± 0.1 2.0 ± 0.1 3.6 ± 0.04 3.6 ± 0.04
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Stability in buffer solutions and in 80 % human serum. Chemical degradation of both
1 and 2 followed first-order kinetics at pH 1.0-9.0 and the half-lives are presented in
Table 5.2. The hydrolysis of 2 was faster than that of 1 at all pH values, probably due to
the aromatic nature around the hydroxyimine structure of ketoprofen, which makes the
hydroxyimine nitrogen less basic than that of 2. Also the bulk aromatic rings around the
carbonyl carbon of 1 increase the steric hindrance, thus slowing down the nucleophilic
attack of the water molecule, which can be understood by examining the mechanism of
hydrolysis illustrated in Scheme 5.3. The nitrogen of hydroxyimine is first protonated,
which leads to the nucleophilic attack of the water molecule to the carbonyl carbon.
Second protonation of the nitrogen makes NH2OH a good leaving group, the C-N bond
breaks and a double bond of the corresponding ketone is formed. The chemical stability
of 2 increases with pH (Table 5.2) and in the pH-range of pH 5.0 to 9.0 the half-lives of 2
are over 16 hours.
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Scheme 5.3. The mechanism of the chemical hydrolysis of hydroxyimine to ketone in
acidic conditions.
Both 1 and 2 showed high stability towards enzymatic hydrolysis in 80% human serum
(pH 7.4) with the half-life of approximately 33 and 25 days, respectively (Table 5.2).
Table 5.2. Rates of hydrolysis of nabumetone hydroxyimine (1) and ketoprofen
hydroxyimine (2) in buffer solutions and human plasma at 37ºC (mean ± SD, n = at least
3, unless otherwise mentioned)
t1/2
min
pH 1.0
t1/2
min
pH 3.0
t1/2
h
pH 5.0
t1/2
days
pH 7.4
t1/2
days
pH 9.0
t1/2
days
80 % human
serum
1 360.0 ± 1.8n=2 n.d. - a - a - a 33.2 ± 2.9
2 6.0 ± 0.15 11.0 ± 0.6  16.3 ± 2.6  12.0 ± 5.0 - a 24.6 ± 4.6
a no degradation was observed during the four weeks’ incubation, n.d. = not determined
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Enzymatic degradation. The oxidation of hydroxyimines was determined in liver
microsomes from humans, untreated rats and rats treated with CYP inducing agents
(dexamethasone (CYP3A), phenobarbital  (CYP2B), 3-methylcholantrene (CYP1A))
(Pelkonen et al. 1998). The half-lives of the oxidation reactions were determined for both
1 and 2 and the formation of ketoprofen also for 1. During the oxidation of 2 two major
metabolites, nabumetone and 6-methoxy-2-naphthylacetic acid (6-MNA) were formed
but were not quantified due to their fast metabolism to several other metabolites.
The oxidation of 2 occurred more than 1000-fold faster than that of 1 with half-lives of
2 to 58 minutes and 72 to 167 hours, respectively (Table 5.3). The degradation of 2 was
the fastest with 3-methylcholanthrene-treated microsomes with the half-life of 2 min
followed by phenobarbital- and dexamethasone-treated rat microsomes, respectively. For
both compounds 1 and 2 the reaction was the slowest in control rat microsomes (t1/2
values were 10020 and 58 min, respectively).
Table 5.3. Half-lives of the oxidation of 1 and 2 in liver microsomes from untreated
(CTRL), dexamethasone (DEX)-, 3-methylcholanthrene (3-MC)- and phenobarbital (PB)-
treated rats and from humans (mean ± SD, n = 3, unless otherwise mentioned).
Microsomes  t 1/2 of 1
min n=1
 t 1/2 of 2
min
Without
microsomes
-a -a
CTRL 10020 58 ± 3.8
DEX 4320 46 ± 5.0
PB 5040 28 ± 2.7
3-MC 6000 2.0 ± 0.16
Human 5016 51± 3.6
a No oxidation was detected during incubation
The formation of ketoprofen from 1 was also affected by enzyme induction, the most
efficient reaction being mediated by dexamethasone pretreated rat liver microsomes
(Table 5.4). These oxidation reactions did not occur without microsomes or NADPH,
proving that the oxidation reactions are catalyzed by microsomal oxidative enzymes.
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Table 5.4. Formation of ketoprofen in liver microsomes from untreated (CTRL),
dexamethasone (DEX)-, 3-methylcholanthrene (3-MC)- and phenobarbital (PB)-treated
rats and from humans.n=1
Incubation
conditions
1a
CTRL 0.12
- NADPH 0.02
DEX 6.72
- NADPH 0.48
+ ketoconazole 2.50
3-MC 1.46
- NADPH 0.14
PB 1.39
- NADPH 0.10
Human 0.80 b
Without microsomes -c
a Results are expressed as nmol of metabolite (mg of protein)-1 (24h)-1. b Results are expressed as nmol of
metabolite (mg of protein)-1 (4h)-1 c No formation of ketoprofen was observed.
The difference in degradation rates between 1 and 2 is significant (Table 5.3). This is
likely due to CYP substrate specificity of the two compounds. Since the active site of
CYP enzymes is negatively charged, 1 bearing a negative charge is suggested to be poor
substrate of CYPs. Also the aromatic rings enhance the steric hindrance around the
hydroxyimine structure and may also explain the slow oxidation rate. Since the oxidation
of 2 was much more effective compared to 1, the metabolism of 2 was investigated in
detail using human recombinant CYP enzymes in vitro.
Formation of nabumetone in human recombinant CYP enzymes. Incubation of 100
µM 2 was performed with eight different human CYP enzymes. All tested CYP forms
(CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4)
metabolized 2 to nabumetone (Table 5.5). The nabumetone formation rate was most rapid
with CYP3A4 and CYP2A6 with rates of 5.6 and 5.4 nmol of metabolite (mg of protein)-1
(60 min)-1, respectively. According to these results it is obvious that the enzymatic
oxidation of hydroxyimine is catalyzed by several human CYP enzymes in vitro.
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All but one CYP form (CYP2C9) followed Michaelis-Menten kinetics and the
parameters Km and Vmax could be determined. Kinetic studies indicated that CYP3A4
possessed the highest Vmax (1600 min-1) and CYP2B6 the lowest (290 min-1) (Table 5.5).
Km values of 2 varied between 40 ?M (CYP2E1) and 200 ?M (CYP3A4).  According to
the specificity constant (Vmax/Km), the most efficient enzymes were CYP2A6 and
CYP2E1 with specificity constants of 11.9 ?M -1 min-1 and 11.0 ?M -1 min-1, respectively.
Table 5.5. Formation of nabumetone from nabumetone hydroxyimine (2) in human
recombinant enzymes (mean ± SD, n = 2) and enzyme kinetic parameters for nabumetone
hydroxyimine (mean, n = 3)
Recombinant
enzyme
Formation
of
nabumetone
from 2a
Km
[µM]
of 2
95%
confidence
intervals
Vmaxb 95%
confidence
intervals
Vmax/
Km
CYP1A2 2.71 ± 0.78 180 0-430 670 140-1190 3.7
CYP2A6 5.42 ± 0.20 90 60-120 1070 900-1240 11.9
CYP2B6 4.65 ± 0.09 70 40-110 290 30-350 4.14
CYP2C9 1.43 ± 0.04 - c - c - c
CYP2C19 4.5 ± 0.52 60 30-90 380 300-450 6.3
CYP2D6 3.96 ± 0.06 90 30-140 870 630-1110 9.7
CYP2E1 4.02 ± 0.01 40 30-60 440 390-480 11
CYP3A4 5.62 ± 0.14 200 30-360 1600 780-2400 8
a Results are expressed as nmol of metabolite (mg of protein)-1 (60 min)-1. b pmol nabumetone (nmol CYP)-
1 (min)-1, c kinetics does not follow Michaelis-Menten kinetics
Determination of nitrite. The release of nitric oxide from 2 during the incubation in
microsomes from dexamethasone induced rats was determined as nitrite via nitrate
reductase by the standard Griess reaction (Jousserandot et al. 1998). Nitric oxide was
formed during the 4 h incubations at almost equimolar quantities, as nabumetone was
formed (11.0 ± 0.8 and 13.0 ± 0.24 nmoln=2, respectively) and it was not formed without
microsomes or without 2. Although small quantities of other unidentified metabolites
were formed during the incubation, this study does demonstrate that nitric oxide is
formed simultaneously with nabumetone during incubation.
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Conversion of nabumetone hydroxyimine to nabumetone in vivo. The conversion of
2 to nabumetone and 6-MNA, the main metabolite of nabumetone, was demonstrated in
vivo in rats after per os administration. Other minor metabolites formed were not assayed.
Since 6-MNA is partially conjugated with glucuronic acid in its metabolism (Davies
1997, Haddock et al. 1984), the amount of 6-MNA was determined after the alkaline
hydrolysis (Mikami et al. 2000) to break the ether bond of the glucuronide. The amounts
of 2 and nabumetone were determined without hydrolysis, since 2 hydrolyzes to
nabumetone under alkaline hydrolysis conditions.
The recovery of the extractions from urine, determined by using naproxen as an
internal reference, was high with an average of 97 % (from 70 to 100 %). The variance of
urine volumes between rats was substantial with an average of 17.9 ± 8.5 ml (from 8.9 to
39.9 ml). In general, the variation between rats was quite high, whether assessed as
nmol/total urine sample or as nmol/ml of urine.
    The amount of 6-MNA in Group 1 administered with 2 was 23 % compared to that
of in Group 2, which were administered with nabumetone (Table 5.6). The combined
quantity of the nabumetone and 6-MNA in the total urine samples of Group 1 was 37 %
of the quantity of 6-MNA in Group 2 (8.4 ± 2.9 and 23.0 ± 8.3 nmol, respectively)
revealing that oxidation of 2 to nabumetone occurs also in vivo. This bioconversion is
thought to be enzymatic after absorption, not chemical in GI-tract. Since the pH of the fed
rat stomach is approximately 4.5 (Davies and Morris 1993) and the relatively large
volume of oil administered can increase the gastric pH, 2 is suggested to be stable enough
to be absorbed intact (t1/2 approx. 16 h at pH 5.0). The reason for unchanged 2 in the rat
urine samples of Group 1 is probably due to the high dose of 2, which may have caused
saturation of the CYP enzymes in the liver. Thus, a part of the prodrug is secreted as
intact prodrug. To some extent, the situation is the same in samples of Group 2 rats, in
which the unchanged nabumetone was also presented in urine. 2 was also found to be
stable enough in rat urine at 37ºC (t1/2 = 69 ± 14 h (n = 4)). No 6-MNA and only small
amounts of nabumetone was formed during the incubation of 2 in rat urine at 37ºC. In
summary, the data shows that 2 is converted to both nabumetone and 6-MNA in rats in
vivo.
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Table 5.6. Formation of nabumetone and 6-MNA from nabumetone hydroxyimine (2) in
vivo in rat (mean ± SD, n = 3)
Animal
group
6-MNA
nmol/total urine /
nmol/ml of urine
2
nmol/total urine /
nmol/ml of urine
Nabumetone
nmol/total urine /
nmol/ml of urine
Group 1a 5.2 ± 1.7 /
0.23 ± 0.06
46.7 ± 32.3 /
1.8 ± 1.0
3.3 ± 1.6 /
0.15 ± 0.08
Group 2b 23.0 ± 8.3 /
1.48 ± 0.75
n.d.d 9.3 ± 4.9 /
0.59 ± 0.46
Group 3c n.d.d n.d.d n.d.d
 a Rats received 105 mg /kg of 2, b Rats received 100 mg / kg of nabumetone, c CTRL rats received 2 ml of
turnip rape oil, d not detected
Determination of ALAT and CRP. NO plays an important physiological role in the
liver, the effect being either protective or toxic depending on the source of NO (Baumann
and Gauldie 1994). The levels of alanine aminotransferase (ALAT) and C-reactive
protein (CRP) in rat serum samples were assayed to determine whether administration of
2 and the released NO could evoke tissue damage in liver. Damage to liver cells leads to
the release of acute phase protein ALAT and inflammation, reflected by elevated CRP
levels in serum (Baumann and Gauldie 1994).
The levels of ALAT and CRP were similar in groups 1-3 and no differences between
rats administered with nabumetone or 2 and control rats were detected. ALAT values
were 70 ± 11, 70 ± 13 and 71 ± 11 U/l for groups 1, 2 and 3, respectively. CRP values
were 4.2 ± 0.4 mg/l for each group. This result suggests that no overt acute toxic reaction
occurred in rats fed with 2.
5.3 Conclusions
Hydroxyimine derivatives of ketones offer a feasible tool to modify properties of drugs
containing the ketone functionality. The results show that nabumetone hydroxyimine (2)
was oxidized to nabumetone in vitro by microsomal CYP enzymes. Activation of 2 to
nabumetone and other metabolites occurred also in vivo in rats. Urine samples of 2
treated rats contained nabumetone, 6-MNA and also 2 probably due to treatment with
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high dose of prodrug causing the saturation of liver enzymes. The present study shows
that the hydroxyimine structure is activated to the corresponding ketone both in vitro and
in vivo and the released nitric oxide causes no acute liver toxicity after peroral
administration in rats. Detailed studies on each oxime derivative of hydroxyimine are
needed for the full characterization of the physicochemical properties, especially
chemical stability and the activation of prodrugs. The present study reveals that the
hydroxyimine is a potential intermediate prodrug structure especially for ketone drugs,
and can easily been further derivatized using appropriate pro-moieties depending upon
the purpose of prodrug application.
5.4 Methods
Synthesis. The 1H NMR parameters have been solved precisely with the PERCHit
iterator (Laatikainen et al. 1996) under PERCH software version 2004 (PERCH Solutions
Ltd, Kuopio, Finland).
2-{3-[(E,Z)-(hydroxyimino)(phenyl)methyl]phenyl}propionic acid (1). 2-(3-
benzoylphenyl)propanoic acid (2.0 g, 7.86 mmol), hydroxylamine hydrochloride (1.52 g,
21.9 mmol) and pyridine (1.76 ml, 21.9 mmol) were dissolved in dioxane (50 ml) and
refluxed for 24 h. Solvent was evaporated and the residue was diluted with 40 ml
saturated Na2CO3. The obtained solution was washed twice with diethylether (40 ml).
The water phase was acidified with concentrated HCl and extracted with diethylether (3 ×
30 ml). The organic phase was dried over Na2SO4 and evaporated to dryness to give a
mixture of 1a 2-{3-[(E)-(hydroxyimino) (phenyl)methyl]phenyl}propanoic acid and 1b
2-{3-[(Z)-(hydroxyimino)(phenyl)methyl] phenyl}propanoic acid as a white solid (1.59 g,
75 %, E:Z ratio 50:50). 1a: 1H NMR (CDCl3) ? 7.79 (1H, t, 4JHH=1.79 and 1.76), 7.43
(5H, bs), 7.35 (1H, dt, J=7.71 and 1.79), 7.24 (1H, t, J=7.71, 7.81), 7.02 (1H, dt, J= 7.81
and 1.76), 3.83 (1H, q, J=7.18), 1.60 (3H, d) ); 13C NMR: ???178.84 s, 157.26 s, 140.48 s,
136.17 s, 132.38 s, 129.45 d (2C), 128.95 d, 128.56 d, 128.21 d (2C), 128.13 d 126.98 d,
45.49 d, 17.60 q. 1b: 1H NMR (CDCl3) ? 7.46-7.30 (9H, m), 3.80 (1H, q, J=7.2), 1.53
(3H, d); 13C NMR: ? 179.64 s, 157.39 s, 140.03 s, 135.91 s, 132.76 s, 129.69 d, 129.50 d,
129.07 d, 128.50 d, 128.44 d (2C), 128.03 d (2C), 45.20 d, 17.94 q. ESI-MS: 268.0 (M –
1). Anal. (C16H15NO3) C, H, N.
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(2E)-4-(6-methoxy-2-naphthyl)butan-2-one oxime and (2Z)-4-(6-methoxy-2-
naphthyl) butan-2-one oxime (2). 4-(6-methoxy-2-naphthyl)butan-2-one (1 g, 4.38
mmol), hydroxylamine hydrochloride (609 mg, 8.76 mmol) and pyridine (707 ?l, 8.76
mmol) were dissolved in ethanol (22 ml) and refluxed for 24 h. Solvent was evaporated
and the residue was diluted with Et2O. The obtained solution was washed with saturated
Na2CO3 and water, dried over Na2SO4 and evaporated to dryness. Flash chromatography
on SiO2 (petrol ether:ethyl acetate 4:1) gave a mixture of 2a, (2E)-4-(6-methoxy-2-
naphthyl)butan-2-one oxime and 2b, (2Z)-4-(6-methoxy-2-naphthyl)butan-2-one oxime
as a white solid (total yield  1 g, 4.12 mmol, 94 %). 2a: 1H NMR (CDCl3) ? 8.20 (1H, bs),
7.664 (1H, d, J=8.56), 7.662 (1H, d, J=8.82), 7.55 (1H, d, 4JHH=1.80), 7.29 (1H, dd,
J=8.56 and 1.80), 7.12 (1H, dd, J=8.82 and 2.56), 7.10 (1H, d, 4JHH=2.56),  3.90 (3H, s),
2.96 (2H, dd*, J=10.36 and 5.83), 2.58 (2H, dd*), 1.93 (3H, s); 13C NMR: ? 158.03 s,
157.30 s, 136.26 s, 133.15 s, 129.12 s, 128.96 d, 127.54 d, 126.93 d, 126.28 d, 118.77 d,
105.71 d, 55.30 q, 37.73 t, 32.59 t, 13.76 q. 2b: 1H NMR (CDCl3) ? 8.01 (1H, bs), 7.674
(1H, d, J= 8.37), 7.674 (1H, d, J= 8.96), 7.59 (1H, d, 4JHH=1.70), 7.34 (1H, dd, J=8.37 and
1.70), 7.12 (1H, dd, J=8.96 and 2.60), 7.11 (1H, d, 4JHH=2.60), 3.91 (3H, s), 2.97 (2H,
dd*, J=9.85 and 6.25), 2.75 (2H, dd*), 1.83 (3H, s); 13C NMR: ? 158.54 s, 157.31 s,
136.40 s, 131.17 s, 129.11 s, 128.99 d, 127.57 d, 126.90 d, 126.23 d, 118.76 d, 105.71 d,
55.30 q, 31.51 t, 30.62 t, 20.36 q. *as typically, this Z-CH2CH2-Y is analysed as AA'BB'-
spinsystem due to strong trans orientation (here the system is insensitive to geminal
coupling and is not analysed). ESI-MS: 244.0 (M+1). Anal. C15H17NO2: C, H, N.
HPLC analysis. HPLC analysis was performed using a Beckman HPLC system, which
consisted of a Beckman System Gold Programmable Solvent Module 126, a Beckman
System Gold Detector Module 166 (wavelength 254 nm for ketoprofen and 1; 225 nm for
nabumetone and 2) and Beckman System Gold Autosampler 507e and a Zorbax Eclipse
SB-C18 (4.6 mm × 150 mm, 5 ?m) analytical column (Agilent Technologies Inc., Little
Falls, Wilmington, DE, USA). Separations were performed with isocratic elution by
using a mobile phase consisting of either 90 % (v/v) acetonitrile and 2.2 % (v/v) acetic
acid with a ratio of 50:50 (ketoprofen and 1) or 90 % (v/v) acetonitrile and 20 mM
phosphate buffer (pH 2.5) with a ratio of 40:60 (nabumetone and 2) at a flow rate of 1.0
ml/min at 25ºC.
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Preparation of human hepatic microsomes. Human liver samples were obtained
from the University Hospital of Oulu as surplus from kidney transplantation donors
(approved by the Ethics Committee of the Medical Faculty of the University of Oulu,
Oulu, Finland). The livers were transferred to ice immediately after surgical excision, cut
into pieces, snap-frozen in liquid nitrogen and stored at -80°C until the microsomes were
prepared by standard differential ultracentrifugation. The metabolic characteristics of
these microsomes have been published earlier (Turpeinen et al. 2005). A weight-balanced
microsomal pool of seven liver microsomal preparations which have been extensively
characterized for primary metabolic screening was employed. Baculovirus-insect cells
expressing human CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6,
CYP2E1 and CYP3A4 were purchased from Gentest Corp (Woburn, MA, USA).
Preparation of rat hepatic microsomes. Male wistar rats (150-200 g) were treated i.p.
for four days with either phenobarbital (80 mg/kg/day in 0.9% NaCl solution), 3-
methylcholanthrene (20 mg/kg/day in olive oil), dexamethasone (50mg/kg/day in olive
oil) or 0.5 ml olive oil (control rats) (Jousserandot et al. 1998). Microsomes were
prepared as previously reported (Pearce et al. 1996) and stored at -80°C until use. Protein
concentrations were determined by using the Biorad Protein Assay (Bio-Rad, Hercules,
CA, USA), and cytochrome P450 contents were determined as reported earlier (Omura
and Sato 1964).
In vitro metabolism and enzyme kinetic analyses of hydroxyimines. The in vitro
metabolism of 1 and 2 was evaluated in isolated liver microsomes from humans, from
untreated rats and from rats treated with inducing agents. A typical incubation mixture, in
a final volume of 150 µl-1500 µl, contained 20 µM prodrugs in phosphate buffer for 1
and in ethanol for 2, 50 mM sodium phosphate buffer (pH 7.4) and 100µl liver
microsomes. Ethanol concentration was 1 % or less. The reaction was started by the
addition of a NADPH-regenerating system (1.15 mM NADP, 12.5 mM isocitric acid,
56.25 mM KCl, 187.5 mM Tris-HCl, pH 7.4 12.5 mM MgCl2, 0.0125 mM MnCl2 and 1.2
U isocitric acid dehydrogenase) following 2 minutes of pre-incubation at 37°C. In blank
solutions liver microsomes and in samples without NADPH, the NADPH solution was
replaced with the same volume of water. The reactions were terminated by the addition of
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the same amount of ice-cold acetonitrile as the sample. The samples were kept on ice,
centrifuged for 15 min at 11000 rpm, and the supernatant was analyzed by the HPLC.
Incubations of 2 with human recombinant P450s were performed using conditions
described before for liver microsomes, except the mixture contained 5 pmol of P450
(CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4)
instead of microsomes. Enzyme kinetic studies of oxidation of 2 to nabumetone by
CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4
were also conducted in the same conditions using 10 µM-200 µM of 2 and incubating for
60 min.
Pseudo-first-order half-lives (t1/2) for the enzymatic degradation of prodrug at different
liver microsomes were calculated from the slope of the linear portion of the plotted
logarithm of remaining prodrug versus time.
Determination of nitrite. For the determination of nitrite (NO2-), enzymatic
incubations in microsomes were performed similarly as described above, except that 100
?M solution of 2 was used and nitrate reductase (60mU from Aspergillus Niger) was
added after three hours to incubation medium to reduce available nitrate (NO3- to nitrite
NO2-) and the incubation was continued for 1 hour. After four hours of incubation, the
reaction was stopped by heating samples for 5 min at 100°C to precipitate proteins and to
eliminate the bleaching effect of NADPH on the Griess reaction. The samples were
centrifuged for 15 min at 11000 rpm. The concentration of nitrite in the supernatants were
determined by the Griess reaction, where 210 µl of sulfanilamide (1.8% w/v) solution in
1M HCl solution and 140 µl of N-(1-naphthyl)ethylenediamide dihydrochloride (0.3%
w/v) solution in 1M HCl solution were added to 700 µl of the supernatants before
analysis at an absorbance of 548 nm. For the standard curve, solutions of known nitrite
concentrations (0 - 40 µM sodium nitrite solution) were prepared into the mixture of 50
mM phosphate buffer pH 7.4 and 5 mM MgCl2 solution, and the absorbance was
measured after treatment with Griess reagents. Quantitations of total NO2- were obtained
from the resulting standard curve.
Animal treatments. Nabumetone and 2 were dissolved in 10.0 mg/ml and 10.5 mg/ml
turnip rape oil, respectively. Wistar male rats (aged, weight 221-339 g) were randomly
assigned into three groups of five rats. Rats were adapted for 48 h to metabolic cages.
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After 24 h, urine and feces were collected and rats were treated by administering either 2
(100 mg/kg, Group 1), nabumetone (105 mg/kg, Group 2) or oil only (2 ml / rat, Group 3)
by gavage. After 24 h of drug administration, the rats were decapitated and urine, blood
and liver samples were collected and frozen at -78ºC.
Rat urine sample preparations. Rat urine samples were frozen and stored at -78ºC
until analysis. 2, nabumetone and 6-MNA were analyzed by diluting 250 ?l of urine
sample with 210 ?l of water and vortex mixed. 40 ?l of internal standard solution
(naproxen) was added. 2 and nabumetone were applied to the C18 solid-phase extraction
cartridges (Discovery DSC-18; Supelco, Bellefonte, PA, USA), dried by aspiration of air,
eluted with 3 ml of 40 % hexane in ethyl acetate and evaporated to dryness under a
nitrogen stream at 40 ºC. 250 ?l of 1 M NaOH-solution was added to the sample
containing 6-MNA, vortex mixed and allowed to stand for 1 h at room temperature. 250
?l of 1 M HCl-solution was added, vortex mixed and applied to the C18 solid-phase
extraction cartridges. After drying the analytes were eluted with 3 ml of 40 % hexane in
ethyl acetate and evaporated to dryness under a nitrogen stream at 40 ºC. After
evaporation, the samples were dissolved to 250 ?l of 50 % acetonitrile in water and
measured by HPLC. The quantities of analytes were determined using external, rat urine
spiked standards (nabumetone, 2 and 6-MNA) and the recovery of the extractions was
determined with internal standard (naproxen).
Stability of 2 in rat urine. The rate of hydrolysis of 2 was determined in rat urine at
37°C. 160 µL of the solution of 2 in 50 % acetonitrile (0.75 µg/ml) was placed to the
test tube and evaporated to dryness under a nitrogen stream at 40ºC. 2 ml of preheated
rat urine was added to the tubes and the solutions were placed in a thermostatically
controlled water bath at 37ºC. 230 µl samples of solution were taken at appropriate time
intervals. 250 µl of water and 20 µl of naproxen solution (0.51 µg/ml in 50 %
acetonitrile) was added to the samples, vortex mixed and applied to the preconditioned
and equilibrated C18 solid-phase extraction cartridges (Discovery DSC-18; Supelco,
Bellefonte, PA, USA). The test tube was washed with 500 ?l of water, added to the
cartridge and dried by aspiration of air. The analytes were eluted with 3 ml of 40 %
hexane in ethyl acetate and evaporated to dryness under a nitrogen stream at 40 ºC.
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After evaporation, the samples were dissolved to 250 ?l of 50 % acetonitrile in water
and measured by HPLC as previously described with rat urine samples.
Determination of ALAT and CRP from rat liver samples. The analysis of amounts
of alanineaminotransferase (ALAT) and C-reactive protein (CRP) was performed at the
Laboratory Centre of Kuopio University Hospital. The ALAT assay was performed by a
kinetic method (by ECCLS/IFCC guideline) and CRP assay by immunoturbidometrics.
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6 1-CHLOROETHYL PHOSPHATES AND PHOSPHORAMIDATES AS
BUILDING BLOCKS OF PRODRUGS *
Abstract: A versatile, efficient and simple method for the preparation of various 1-
chloroethyl phosphates and phosphoramidates was developed. The protected
chlorophosphate or phosphoramidate was synthesized to the vinyl derivative under mild
conditions, followed by the conversion to the 1-chloroethyl phosphate or
phosphoramidate by dry HCl-gas resulting in good to excellent yields. This method was
further improved by the use of microwaves. The protected vinyl chlorophosphates
underwent fast microwave-assisted conversion to the 1-chloroethyl phosphates in the
presence of HCl with excellent yields up to 900-times faster than at standard NTP
conditions. 1-Chloroethyl phosphates and phosphoramidates could be used as building
blocks for the synthesis of novel ethylidene linked phosphate prodrugs.
* Adapted with permission from:
Kumpulainen H, Järvinen T, Saari R, Lehtonen M, Vepsäläinen, J. An efficient strategy
for the synthesis of 1-chloroethyl phosphates and phosphoramidates: The Journal of
Organic Chemistry 70: 9056-8, 2005. Copyright 2007 American Chemical Society
and
Kumpulainen H, Saari R, Lehtonen M, Rautio J, Järvinen, T, Vepsäläinen, J.
Convenient microwave-assisted synthesis of 1-chloroethyl phosphates: Tetrahedron
Letters 47: 2003-2004, 2006. Copyright 2007 Elsevier Science.
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6.1 Introduction
Phosphates and phosphoramidates are widely used as prodrug structures to enhance
water-solubility (Fleisher et al. 1996) or to increase the therapeutic potential of a parent
drug (Chang et al. 2001, Egron et al. 2003, Freel Meyers and Borch 2000). The
phosphoramidates are also used to synthesize phosphate esters with different protecting
groups by the replacement of an amide with an ester group (Alberg et al. 1992, Mathé et
al. 1998). In addition, they can be used to synthesize a monoester phosphate prodrug by
hydrolysing the phosphoramide bond (Garrison and Boozer 1968). Phosphate
promoieties are often attached to the parent drug via an oxymethyl spacer group (Krise
et al. 1999, Mäntylä et al. 2004, Ueda et al. 2003), but this can give rise to a problem
since the highly toxic formaldehyde (Slikker et al. 2004) is released systemically during
metabolism of the oxymethyl group in the body (Nudelman et al. 2001, Nudelman et al.
2005). In order to overcome this drawback, we were interested in developing ethylidene
linked prodrugs, which are metabolized to the less toxic acetaldehyde. Previously, an
ethylidene spacer group has been used in (acyloxy)alkyl prodrugs (Alexander et al.
1991, Sum et al. 1999), but no descriptions of ethylidene linked phosphate prodrugs to
increase the water-solubility of drugs have been published. The compounds described in
the present study could be used as starting materials for the preparation of ethylidene
linked phosphate prodrugs.
The ethylidene phosphate prodrugs could be prepared via addition of 1-chloroethyl
phosphates or phosphoramidates to an appropriate functional group (e.g. hydroxyl or
amine group) of the drug molecule. However, there is no efficient and practical method
to synthesize 1-chloroethyl phosphates or phosphoramidates. The 1-chloroethyl
derivatives of carboxylic acids are traditionally prepared from acetaldehyde and the
corresponding acid chloride using ZnCl2 as the catalyst (Bodor et al. 1980). However,
this method was not successful when applied for the synthesis of 1-chloroethyl
phosphates. The only reported approach to synthesize 1-chloroethyl phosphates is a
method in which diethyl 1-chloroethyl phosphate is synthesized from ethyl
phosphorodichloridate using hazardous chemicals and methods (chlorine gas, mercury
vapour lamp) (Allen 1960). In this present study, an efficient and practical synthetic
approach for the preparation of 1-chloroethyl phosphates and phosphoramidates was
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developed. Protected chlorophosphates or phosphoramidates are synthesized to the
vinyl derivative under mild conditions, followed by the conversion to the 1-chloroethyl
phosphate or phosphoramidate by dry HCl-gas either at NTP conditions or in a
microwave-oven.
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Scheme 6.1. Synthesis of vinyl (2a-i) and 1-chloroethyl phosphates and
phosphoramidates (3a-i).
6.2 Results and Discussion
The desired vinyl intermediates were prepared from the corresponding
chlorophosphates 1, which are commercially available (1b-c, e, and g) or prepared by
the known method from phosphorous trichloride (Mark and van Wazer 1964, Steinberg
1949) (1a, d, f and h) or from diethyl phosphorodichloridate (Quin and Jankowski
1994) (1i). Nine different vinyl phosphates or phosphoramidates were prepared by
treating 1 with the enolate of acetaldehyde (Stowell and Widlanski 1994) with
reasonably good yields (Scheme 6.1, Table 6.1). The vinylation occurred under mild
conditions, which makes it a suitable method for a wide variety of molecules.
The electrophilic addition reaction of HCl to the vinyl double-bond was initially
obtained by bubbling dry HCl gas through a solution of 2 in dry ethyl acetate. The
reaction occurs via an attack of H+ to yield an intermediate carbo-cation, which quickly
undergoes a reaction with a negative halide ion to yield an alkyl halide (Scheme 6.2).
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Scheme 6.2. The electrophilic addition reaction of HCl to vinyl phosphate
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The results listed in Table 6.1 show that there are major differences in the reaction
times and conditions depending on the chemical nature of the phosphate substituents.
The compounds 3h and 3i were readily obtained under mild conditions, but on the other
hand, the diphenyl derivative 2g did not react at all, even though several common
catalysts and over pressure (5 atm) were tested. In order to determine, whether the
microwave-assisted synthesis would provide some benefits compared to the method at
NTP conditions, the addition reaction of HCl to vinyl ester of phosphates (Scheme 6.1)
was studied in a microwave oven.
Table 6.1. Synthesis of vinyl and chloroethylidene phosphates and phosphoramidatesa
NTP conditions: Microwave-
assisted:
R R’ 2: yield
%
3: yield
%
Time
(h) b
3: yield
%
Time
(h)
1a: Me OMe 2a: 52 3a: 86 29 (12) c 3a: -f -f
1b: Et OEt 2b: 64 3b: 91 24 (7) c 3b:99 0.25
1c: Cl3Et OCl3Et 2c: 68 3c: 66 912 (195) c 3c:95  1
1d:      Me OPh 2d: 54 3d: 87 500 (50) c 3d:95 0.75
1e:  (2,6-Me2)Ph O-(2,6-Me2)Ph 2e: 35 3e: 92 480 (90) c 3e:96 0.5
1f:         -CH2CH2CH2O- 2f: 76 3f: 98 30 (12)c 3f: 99 0.125
1g:      Ph OPh 2g: 70 3g: - d - d 3g:98 1
1h:      Bz OBz 2h: 30 3h: 68 48e 3h: -f -f
1i:       Me NEt2 2i: 88 3i: 91 21e 3i: -f -f
a Yields without purification. b The reaction times are the total reaction times of step 2, with the times of
HCl-bubbling in parenthesis.  c Reaction conditions: HCl-bubbling, R.T. d Did not react under any kind of
conditions. e Reaction conditions: EtOAc saturated with HCl, 4ºC. f Not examined
The microwave-assisted synthesis of compounds 3b-g was initiated using
trichloroethylvinyl phosphate, which had the longest reaction time under NTP
conditions. Trichloroethylvinyl phosphate 2c was dissolved in ethyl acetate saturated
with dry HCl-gas. The mixture was heated at 176 ºC and 20 bars in a microwave oven
for 60 minutes, after which 95 % of 2c was converted to 1-chloroethyl phosphate 3c. By
comparison, the synthesis under NTP conditions resulted in a yield of 68 % after 195
hours of bubbling (Table 6.1). After these promising results, the microwave-assisted
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reaction was carried out with diphenylvinyl phosphate 2g, which did not react at all
using the previously described method, even if catalysts or higher pressure were used.
With microwave-assisted heating for 60 min at 173 ºC and 20 bar, 98% of
diphenylvinyl phosphate 2g was converted to the corresponding 1-chloroethyl
phosphate 3g. Also, all of the other tested vinyl phosphates reacted under microwave
conditions (Table 6.1) to give excellent yields (>95%) with significantly shorter
reaction times.
All 1-chloroethyl products, except for 3h, could be purified and isolated with silica
gel column chromatography, but some of the products partially decomposed during the
purification procedure. Since the crude products from the synthesis of 3 did not contain
any major impurities according to 1H-, 13C- and 31P-NMR, these building blocks should
be able to be used without further purification. Thus, the yields of 3a-i presented in
Table 6.1 are reported without purification and are estimated from the actual chemical
yields according to purity of 1H- and 31P-NMR spectra, but the NMR data, GC-MS
analyses and elemental analyses (CHNS) were obtained from the purified products.
6.3 Conclusions
A novel method for the synthesis of 1-chloroethyl phosphates and phosphoramidates
was developed. The synthetic route was started with vinylation of chlorophosphate or
phosphoramidate as the starting material, followed by addition of hydrogen chloride to
the vinyl double bond to yield 1-chloroethyl phosphate or phosphoramidate. This
method was found to be versatile and a simple way to synthesize phosphates and
phosphoramidates with various protecting groups and is thus applicable for a wide
range of molecules. In addition, increased yields, shortened reaction times and the
successful synthesis of otherwise unavailable reaction products can be achieved using
microwave-assisted synthesis of 1-chloroethyl phosphates from vinyl phosphates. 1-
Chloroethyl phosphates and phosphoramidates may further be used as building blocks
for the synthesis of ethylidene linked prodrugs.
92
6.4 Methods
Synthesis. The 1H NMR parameters have been solved precisely with the PERCHit
iterator (Laatikainen et al. 1996) under PERCH software version 2004 (see Figure 6.1)
(PERCH Solutions Ltd, Kuopio, Finland). Electron impact or positive chemical
ionization mass spectra were acquired by a gas chromatograph- mass spectrometry
system. The yields of the reactions are illustrated in Table 6.1.
A general method for the preparation of vinyl phosphates 2. To a 100 ml round-
bottom flask dry THF (50 ml) was added under argon and cooled to 0ºC followed by
addition of 1.6 M n-butyl lithium (15 ml, 24 mmol) in hexane at 0ºC. The reaction
mixture was stirred for 0.5 h at 0ºC and then left overnight at 25ºC. After 18 h without
cooling, this enolate of acetaldehyde was added dropwise to the chlorophosphate or
phosphoramidate 1 (25.2 mmol, 1.05 equiv) in THF (5 ml) during 15 minutes at -78ºC.
After the addition was complete, the reaction mixture was allowed to reach room
temperature over 45 minutes and the solvents were evaporated. The residue was
dissolved in CH2Cl2 (50 ml), washed with 10 % sodium phosphate buffer (pH 7.0, 5 ×
15 ml), dried with Na2SO4 and evaporated to dryness. The residue was purified by
column chromatography to yield vinyl derivative 2. The chromatography purification
conditions are described in detail along with a description of each molecule.
A general method for the synthesis of chloroethylidene phosphates 3 at RT
conditions. To a 10 ml round-bottomed flask vinyl phosphate 2 (5.6 mmol) and EtOAc
(2 ml) were added under argon. Dry gaseous HCl was bubbled through the solution (2a-
f). In the case of 3h-i, the solution of 2 in EtOAc was cooled to 4ºC followed by
addition of EtOAc saturated with HCl (2 ml). The progress of the HCl-addition was
monitored by measuring 1H and 31P NMR spectra from the reaction mixture. After the
appropriate reaction time, the solvents were evaporated and the residue was purified by
column chromatography. The reaction time and conditions varied between the reactions
and are illustrated in detail in Table 6.1.
A general method for the synthesis of chloroethylidene phosphates in microwave
oven. Ethyl acetate was saturated with dry HCl-gas by bubbling HCl through the
solution for 15 min. Trichloroethylvinyl phosphate 2c (100 mg, 0.26 mmol) was
dissolved in 4 ml of saturated HCl-ethyl acetate solution. The mixture was heated at 176
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ºC at 20 bar for 60 min in a Biotage Initiator microwave reactor. The progress of the
HCl-addition was monitored by measuring 1H and 31P NMR spectra from the reaction
mixture during the course of the reaction. After the appropriate reaction time, the
solvents were evaporated to dryness. The reaction time and conditions varied between
the reactions and are described in detail along with a description of each molecule.
Phosphoric acid dimethyl ester vinyl ester 2a: Colorless oil. Chromatography
eluent EtOAc:petrol ether 2:3. 1H NMR (CDCl3) ? 6.579 (1H, ddd, J=13.52 Hz, 5.86
Hz, 3JHP=6.52 Hz), 4.933 (1H, ddd, J=13.52 Hz, 2.17 Hz, 4JHP=1.19 Hz), 4.601 (1H,
ddd, J=5.86 Hz, 2.17 Hz, 4JHP=2.67 Hz), 3.825 (6H, d, 3JHP=11.24 Hz Hz); 13C NMR
(CDCl3) ? 142.14 (d, 2JCP = 5.7 Hz), 100.11 (d, 3JCP = 10.2 Hz), 54.69 (d, 2JCP = 6.0 Hz);
31P NMR (CDCl3) ? -2.10. GC-MS m/z 151 (M-1).
Phosphoric acid diethyl ester vinyl ester 2b: Colorless oil. Chromatography eluent
EtOAc:petrol ether 1:3. 1H NMR (CDCl3) ? 6.584 (1H, ddd, J=13.54 Hz, 5.87 Hz,
3JHP=6.50 Hz), 4.901 (1H, ddd, J=13.54 Hz, 2.05 Hz, 4JHP=1.19 Hz), 4.568 (1H, ddd,
J=5.87 Hz, 2.05 Hz, 4JHP=2.71 Hz), 4.174 (4H, dq, J=7.08 Hz, 3JHP=8.28 Hz), 1.363
(6H, td, J=7.08 Hz, 3JHP=1.01 Hz); 13C NMR (CDCl3) ? 142.17 (d, 2JCP = 5.6 Hz), 99.63
(d, 3JCP = 10.4 Hz), 64.33 (d, 2JCP = 5.8 Hz), 16.00 (d, 3JCP = 6.6 Hz); 31P NMR (CDCl3)
? -4.28. GC-MS m/z 180 (M).
Phosphoric acid bis-(2,2,2-trichloro-ethyl) ester vinyl ester 2c: Colorless oil.
Chromatography eluent EtOAc:petrol ether 1:2. 1H NMR (CDCl3) ? 6.630 (1H, ddd,
J=13.44 Hz, 5.78 Hz, 3JHP=6.71 Hz), 5.082 (1H, ddd, J=13.44 Hz, 2.59 Hz, 4JHP=1.30
Hz), 4.758 (1H, ddd, J=5.78 Hz, 2.59 Hz, 4JHP=2.66 Hz), 4.680 (4H, d, 3JHP=6.90 Hz);
13C NMR (CDCl3) ? 141.34 (d, 2JCP = 6.2 Hz), 102.17 (d, 3JCP = 10.6 Hz), 94.34 (d, 3JCP
= 10.6 Hz), 77.42 (d, 2JCP = 4.5 Hz); 31P NMR (CDCl3) ? -7.59. GC-MS m/z 387 (M).
Phosphoric acid methyl ester phenyl ester vinyl ester 2d: Colorless oil.
Chromatography eluent EtOAc:petrol ether 1:4. 1H NMR (CDCl3) ? 7.346 (2H, m,
J=8.05 Hz, 7.40 Hz, 4JHH=-1.74 Hz, 5JHH= 0.77 Hz) , 7.218 (2H, m, J=8.05 Hz, 4JHH=-
1.20 Hz, -1.17 Hz, 5JHH= 0.77 Hz, 4JHP=1.19 Hz), 7.195 (1H, m, J=7.40, 4JHH=-1.17),
6.634 (1H, ddd, J=13.50 Hz, 5.82 Hz and 3JHP=6.59 Hz), 4.966 (1H, ddd, J=13.50 Hz,
2.27 Hz and 4JHP=1.19 Hz), 4.825 (1H, ddd, J=5.82 Hz, 2.27 Hz and 4JHP=2.80 Hz),
3.908 (3H, d, 3JHP=11.51 Hz); 13C NMR (CDCl3) ? 150.36 (d, 2JCP = 6.9 Hz), 141.99 (d,
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2JCP = 5.9 Hz), 129.85, 125.47, 120.01 (d, 3JCP = 4.8 Hz), 100.70 (d, 3JCP = 10.5 Hz),
55.23 (d, 2JCP = 6.2 Hz); 31P NMR (CDCl3) ? -8.79. GC-MS m/z 215 (M + 1).
 Phosphoric acid bis-(2,6-dimethyl-phenyl) ester vinyl ester 2e: Colorless oil.
Chromatography eluent EtOAc:petrol ether 1:20. 1H NMR (CDCl3) ? 7.044-6.977 (6H,
m), 6.661 (1H, ddd, J=13.49 Hz, 5.77 Hz and 3JHP=5.78 Hz), 4.840 (1H, ddd, J=13.49
Hz, 2.19 Hz and 4JHP=1.01 Hz), 4.525 (1H, ddd, J=5.77 Hz, 2.19 Hz and 4JHP=3.91 Hz),
2.343 (s, 12H); 13C NMR (CDCl3) ? 147.99 (d, 2JCP = 8.6 Hz), 142.45 (d, 2JCP = 5.4 Hz),
130.29 (d, 3JCP = 3.4 Hz), 129.16 (d, 4JCP = 1.5 Hz), 125.54  (d, 5JCP = 1.7 Hz), 99.57 (d,
3JCP = 11.3 Hz), 17.00; 31P NMR (CDCl3) ? -14.69. GC-MS m/z 333 (M + 1).
2-vinyloxy-[1,3,2]dioxaphosphinane 2-oxide 2f: Colorless oil. Chromatography
eluent EtOAc:petrol ether 1:1. 1H NMR (CDCl3) ? 6.611 (1H, ddd, J=13.56 Hz, 5.87 Hz
and 3JHP=7.47 Hz), 4.962 (1H, ddd, J=13.56 Hz, 2.28 Hz and 4JHP=1.21 Hz), 4.637 (1H,
ddd, J=5.87 Hz, 2.28 Hz and 4JHP=2.12 Hz), 4.520-4.400 (4H, m), 2.390-2.287 (1H, m),
1.834-1.779 (1H, m); 13C NMR (CDCl3) ? 141.64 (d, 2JCP = 5.7 Hz), 100.22 (d, 3JCP =
9.9 Hz), 69.23 (d, 2JCP = 6.3 Hz), 25.42 (d, 3JCP = 7.3 Hz); 31P NMR (CDCl3) ? -11.15.
GC-MS m/z 165 (M + 1).
Phosphoric acid diphenyl ester vinyl ester 2g: Light-yellow oil. Chromatography
eluent EtOAc:petrol ether 1:4. 1H NMR (CDCl3) ? 7.451 (4H, m, J=8.20 Hz, 7.44 Hz,
4JHH=-2.35 Hz, 5JHH= 0.55 Hz), 7.290 (2H, m, J=7.44, 4JHH=-1.04), 7.265 (4H, m,
J=8.20 Hz, 4JHH=-2.06 Hz, -1.04 Hz, 5JHH= 0.55 Hz, 4JHP=1.22 Hz), 6.845 (1H, ddd,
J=13.34 Hz, 5.76 Hz and 3JHP=6.82 Hz), 5.056 (1H, ddd, J=13.34 Hz, 2.38 Hz and
4JHP=1.23 Hz), 4.825 (1H, ddd, J=5.76 Hz, 2.38 Hz and 4JHP=2.79 Hz).
Phosphoric acid dibenzyl ester vinyl ester 2h: Colorless oil. Chromatography eluent
EtOAc:petrol ether 1:4. 1H NMR (CDCl3) ? 7.386-7.314 (12H, m), 6.529 (1H, ddd,
J=13.51 Hz, 5.85 Hz and 3JHP=6.51 Hz), 5.083 (4H, d, 3JHP=8.23), 4.862 (1H, ddd,
J=13.51 Hz, 2.16 Hz and 4JHP=1.23 Hz), 4.544 (1H, ddd, J=5.85 Hz, 2.16 Hz and
4JHP=2.70 Hz); 13C NMR (CDCl3) ? 141.96 (d, 2JCP = 5.9 Hz), 135.40 (d, 3JCP = 6.9 Hz),
128.69, 128.62, 128.04, 100.23 (d, 3JCP = 10.4 Hz), 69.77 (d, 2JCP = 5.6 Hz); 31P NMR
(CDCl3) ? 3.93. GC-MS m/z 305 (M + 1).
N,N-diethylphosphoramidic acid methyl ester vinyl ester 2i: Colorless oil.
Chromatography eluent EtOAc:petrol ether 1:1. 1H NMR (CDCl3) ? 6.576 (1H, ddd,
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J=13.60 Hz, 5.93 Hz and 3JHP=6.73 Hz), 4.827 (1H, ddd, J=13.60 Hz, 1.76 Hz and
4JHP=1.33 Hz), 4.505 (1H, ddd, J=5.93 Hz, 1.76 Hz and 4JHP=2.21 Hz), 3.722 (3H, d,
3JHP=11.32 Hz), 3.104 (4H, dq, J=7.11 Hz, 3JHP=11.87 Hz), 1.122 (6H, t, J=7.11 Hz; 13C
NMR (CDCl3) ? 142.39 (d, 2JCP = 5.3 Hz), 98.88 (d, 3JCP = 10.2 Hz), 53.05 (d, 2JCP = 5.7
Hz), 39.79 (d, 2JCP = 4.5 Hz), 14.17 (d, 3JCP = 1.5 Hz); 31P NMR (CDCl3) ? -9.14. GC-
MS m/z 193 (M).
Phosphoric acid 1-chloro-ethyl ester dimethyl ester 3a: Colorless viscose oil.
Chromatography eluent hexane:EtOAc 1:1. 1H NMR (CDCl3) ? 6.242 (1H, dq, J=5.62
Hz, 3JHP=7.62 Hz), 3.837* (3H, d, 3JHP=11.44 Hz), 3.802* (3H, d, 3JHP=11.31), 1.856
(3H, dd, J=5.62 Hz, 4JHP= 1.09 Hz); 13C NMR (CDCl3) ? 85.78 (d, 2JCP = 6.4 Hz),
54.82* (d, 2JCP = 6.1 Hz), 54.55* (d, 2JCP = 6.0 Hz), 27.54 (d, 3JCP = 8.4 Hz); 31P NMR
(CDCl3) ? -0.76. GC-MS m/z 189 (M + 1), 153 (M - Cl). Anal. Calcd for C4H10ClO4P ·
0.7 HCl: C, 22.44; H, 5.04. Found: C, 22.53; H, 4.76. *Due to their chiral center, OMe-
signals have different chemical shifts.
Phosphoric acid 1-chloro-ethyl ester diethyl ester 3b: MW-conditions: 0.25 hours,
100 ºC, 6 bars. Yellow viscose oil. Chromatography eluent hexane:EtOAc 1:1. 1H NMR
(CDCl3) ? 6.247 (1H, dq, J=5.61 Hz, 3JHP=7.79 Hz), 4.201* (1H, ddq, 2JHH= -10.07 Hz,
J=7.10 Hz, 3JHP= 7.79 Hz), 4.184* (1H, ddq, 2JHH= -10.07 Hz, J=7.05 Hz 3JHP=8.05 Hz),
4.159* (1H, ddq, 2JHH= -10.13 Hz, J=7.08 Hz, 3JHP= 8.08 Hz), 4.136* (1H, ddq, 2JHH= -
10.13 Hz, J=7.06 Hz, 3JHP= 7.99 Hz), 1.845 (3H, dd, J=5.61 Hz, 4JHP= 1.03 Hz), 1.368
(3H, ddd, J=7.10 Hz, 7.05 Hz, 4JHP=1.13 Hz), 1.358 (3H, ddd, J=7.08 Hz, 7.06 Hz,
4JHP=1.09 Hz); 13C NMR (CDCl3) ? 85.72 (d, 2JCP = 6.3 Hz), 64.58* (d, 2JCP = 6.1 Hz),
64.33* (d, 2JCP = 5.8 Hz), 27.65 (d, 3JCP = 8.2 Hz), 16.02 (d, 3JCP = 6.9 Hz); 31P NMR
(CDCl3) ? -3.11. GC-MS m/z 217 (M + 1), 181 (M - Cl). Anal. Calcd for C6H14ClO4P ·
0.6 HCl: C, 30.22; H, 6.17. Found: C, 29.98; H, 5.94.
*Due to the chiral center and prochirality there are four 1H and two 13C chemical shifts
for OCH2-groups
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Figure 6.1. As an example of the complicated structure of the spectra with the
calculated and observed 1H NMR spectrum for OCH2-protons signals of 3b
Phosphoric acid 1-chloro-ethyl ester bis-(2,2,2-trichloro-ethyl) ester 3c: MW-
conditions: 1 hour, 176 ºC, 20 bars. Colorless viscose oil. Chromatography eluent
CH2Cl2:hexane:EtOAc (gradient). 1H NMR (CDCl3) 1H NMR (CDCl3) ? 6.332 (1H,
dq, J=5.63 Hz, 3JHP=7.40 Hz), 4.716* (1H, dd, 2JHH= -10.97 Hz, 3JHP=6.82 Hz), 4.667*
(1H, dd, 2JHH= -7.03 Hz, 3JHP=6.88 Hz), 4.666* (1H, dd, 2JHH= -10.97 Hz, 3JHP=6.59
Hz), 4.661* (1H, dd, 2JHH= -7.03 Hz, 3JHP=6.44 Hz), 1.919 (3H, dd, J=5.63 Hz, 4JHP=
1.35 Hz); 13C NMR (CDCl3) ? 94.28, 86.27 (d, 2JCP = 6.8 Hz), 77.44* (d, 2JCP = 4.4 Hz),
77.27* (d, 2JCP = 4.2 Hz), 27.35 (d, 3JCP = 8.8 Hz); 31P NMR (CDCl3) ? -6.18. GC-MS
m/z 423 (M), 389 (M - Cl). Anal. Calcd for C6H8 Cl7O4P · 0.3 EtOAc: C, 19.23; H, 2.33.
Found: C, 19.15; H, 2.21.
*Due to the chiral center and prochirality there are four 1H and two 13C chemical shifts
for OCH2-groups
Phosphoric acid 1-chloro-ethyl ester methyl ester phenyl ester 3d: MW-
conditions: 0.75 hours, 100 ºC, 6 bars. White solid. Chromatography eluent CH2Cl2.
Major isomer ca. 80%: 1H NMR (CDCl3) ? 7.380-7.325 (2H, m), 7.260-7.179 (3H, m),
6.328-6.271 (1H,m), 3.929 (3H, d, 3JHP=11.69 Hz), 1.796 (3H, d, J=5.60 Hz); 13C NMR
(CDCl3) ? 150.13 (d, 2JCP = 7.0 Hz), 129.82, 125.54, 120.06 (d, 3JCP = 4.7 Hz), 86.08 (d,
2JCP = 6.2 Hz), 55.30 (d, 2JCP = 6.3 Hz), 27.34 (d, 3JCP = 8.6 Hz); 31P NMR (CDCl3) ? -
6.94; Minor isomer ca 20%: ? 7.380-7.325 (2H, m), 7.260.7.179 (3H, m), 6.342-6.280
4,240 4,220 4,200 4,180 4,160 4,140 4,120 4,100
Calculated
Observed
c:\perch\hanna-3b.obs
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(1H,m), 3.887 (3H, d, 3JHP=11.59 Hz), 1.888 (3H, d, J=5.64 Hz). 13C NMR (CDCl3) ?
150.13 (d, 2JCP = 7.0 Hz), 129.77, 125.46, 120.06 (d, 3JCP = 4.7 Hz), 85.99 (d, 2JCP = 7.2
Hz), 55.30 (d, 2JCP = 6.3 Hz), 27.55 (d, 3JCP = 8.6 Hz); 31P NMR (CDCl3) ? -7.46.  GC-
MS m/z 251 (M + 1), 215 (M - Cl). Anal. Calcd for C9H12ClO4P: C, 43.13; H, 4.83.
Found: C, 43.21; H, 5.05.
Phosphoric acid 1-chloro-ethyl ester bis-(2,6-dimethyl-phenyl) ester 3e: MW-
conditions: 0.5 hours, 170 ºC, 20 bars. Colorless viscose oil. Chromatography eluent
CH2Cl2. 1H NMR (CDCl3) 1H NMR (CDCl3) ? 7.050-6.969 (6H, m), 6.285 (1H, dq,
J=5.52 Hz, 3JHP=7.62 Hz), 2.403* (6H, s), 2.303* (6H, s), 1.694 (3H, dd, J=5.52 Hz);
13C NMR (CDCl3) ? 147.95 (d, 3JCP = 8.7 Hz), 147.76 (d, 3JCP = 8.7 Hz), 130.42 (d, 2JCP
= 3.4 Hz), 130.34 (d, 2JCP = 3.4 Hz), 129.17 (d, 4JCP = 1.7 Hz), 129.09 (d, 4JCP = 1.7 Hz),
125.60 (d, 5JCP = 2.0 Hz), 125.55 (d, 5JCP = 2.0 Hz), 86.66 (d, 2JCP = 6.4 Hz), 27.22 (d,
3JCP = 8.1 Hz), 17.22, 16.99; 31P NMR (CDCl3) ? -12.99. GC-MS m/z 369 (M + 1), 333
(M - Cl). Anal. Calcd for C18H22ClO4P: C, 58.62; H, 6.01. Found: C, 59.02; H, 6.27.
2-(1-Chloro-ethoxy)-[1,3,2]dioxaphosphinane 2-oxide 3f: MW-conditions: 0.125
hours, 120 ºC, 6 bars. Colorless oil. Chromatography eluent hexane:EtOAc 1:4. 1H
NMR (CDCl3) 1H NMR (CDCl3) ? 6.309 (1H, dq, J=5.59 Hz, 3JHP=8.05 Hz), 4.560-
4.399 (4H, m), 2.390-2.810 (1H, m), 1.879 (3H, dd, J=5.59 Hz, 4JHP= 0.85 Hz), 1.833-
1.773 (1H, m); 13C NMR (CDCl3) ? 85.44 (d, 2JCP = 6.2 Hz), 69.63 (d, 2JCP = 7.4 Hz),
69.00 (d, 2JCP = 7.2 Hz), 27.74 (d, 3JCP = 7.7 Hz), 25.75 (d, 3JCP = 7.4 Hz); 31P NMR
(CDCl3) ? -9.64. GC-MS m/z 201 (M + 1), 165 (M - Cl). Anal. Calcd for C5H10ClO4P:
C, 29.94; H, 5.03. Found: C, 30.06; H, 5.15.
Phosphoric acid 1-chloro-ethyl ester diphenyl ester 3g:  MW-conditions: 1 hour,
173 ºC, 20 bars. Colorless, viscose oil. Chromatography eluent hexane:EtOAc 1:1. 1H
NMR (CDCl3, 500 MHz) ?? ?7.38-7.16 (10H, m), 6.39 (1H, dq, 3JHP = 7.63, 3JHH = 5.61
Hz), 1.75 (3H, dd, 3JHH = 5.61, 4JHP = 1.22 Hz); 13C NMR (CDCl3, 125 MHz) ? 150.24¶
(d, 2JCP = 7.4 Hz), 150.07¶ (d, 2JCP = 7.4 Hz), 129.85 (d, 2JCP = 7.9 Hz), 125.74 (d, 2JCP
= 8.6 Hz), 120.26¶ (d, 3JCP = 4.8 Hz), 120.17¶ (d, 3JCP = 4.4 Hz), 86.41 (d, 2JCP = 6.5
Hz), 27.41 (d, 3JCP = 8.4 Hz); 31P NMR (CDCl3) ? -13.81. GC-MS m/z  312 (M+), 277
(M - Cl). Anal. Calcd for C14H14ClO4P * 0.1 Hexane: C, 54.58; H, 4.83%. Found: C,
98
54.45; H, 4.58%. ¶ Due to the chiral center and prochirality there are two 13C chemical
shifts for ipso- and ortho-carbons.
Phosphoric acid 1-chloro-ethyl ester dibenzyl ester 3h: Colorless viscose oil. 1H
NMR (CDCl3) 1H NMR (CDCl3) ? 7.397-7.298 (10H, m), 6.150 (1H, dq, J=5.49 Hz,
3JHP=7.58 Hz), 5.120-5.051* (4H, m), 1.782 (3H, dd, J=5.49 Hz); 13C NMR (CDCl3) ?
135.18, 128.75, 128.59, 128.28, 85.84, 69.91, 27.54; 31P NMR (CDCl3) ? -1.55.
*Due to the chiral center and prochirality, all four OCH2-signals have different chemical
shifts. Due to decomposition of the product, peaks are broad and the JCP-coupling
constants can not be calculated.
Diethyl-phosphoramidic acid 1-chloro-ethyl ester methyl ester 3i: Slightly yellow
solid. Chromatography eluent 0.5 % MeOH in CH2Cl2. Major isomer ca. 60%: 1H NMR
(CDCl3) ? 6.247-6.189 (1H, m), 3.682 (3H, d, 3JHP=11.38 Hz), 3.178-3.021 (4H, m),
1.828 (3H, dd, J=5.69 Hz, 4JHP=0.72 Hz), 1.141 (6H, t, J=7.14 Hz); 13C NMR (CDCl3) ?
85.04 (d, 2JCP = 5.7 Hz), 52.92 (d, 2JCP = 5.8 Hz), 39.90 (d, 2JCP = 4.8 Hz), 27.87 (d, 3JCP
= 7.6 Hz), 14.04 (d, 3JCP = 2.2 Hz); 31P NMR (CDCl3) ? 10.14. Minor isomer ca. 40%:
1H NMR (CDCl3) ?? ?6.247-6.189 (1H, m), 3.737 (3H, d, 3JHP=11.45 Hz), 3. 178-3.021
(4H, m), 1.819 (3H, dd, J=5.49 Hz, 4JHP=0.71 Hz), 1.116 (6H, t, J=7.08 Hz); 13C NMR
(CDCl3) ? 85.30 (d, 2JCP = 7.0 Hz), 53.12 (d, 2JCP = 5.8 Hz), 39.70 (d, 2JCP = 4.4 Hz),
28.01 (d, 3JCP = 7.2 Hz), 14.06 (d, 3JCP = 2.2 Hz); 31P NMR (CDCl3) ? 10.34. GC-MS
m/z 230 (M + 1), 194 (M - Cl). Anal. Calcd for C7H17ClNO3P: C, 29.94; H, 5.03.
Found: C, 30.06; H, 5.15.
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7 SYNTHESIS, IN VITRO AND IN VIVO CHARACTERIZATION OF
ETHYLIDENE LINKED PHOSPHATE PRODRUG OF PROPOFOL
Abstract. An ethylidene phosphate prodrug of propofol (3) was synthesized and
characterized as a novel phosphate prodrug structure that would represent a safer
alternative for phosphonooxymethyl prodrugs. 3 greatly enhanced the aqueous
solubility of propofol, having solubility over 10 mg/ml. The stability of 3 in buffer
solution (t1/2 = 5.2 ± 0.2 days at pH 7.4, r.t.) was sufficient for i.v. administration. The
enzymatic hydrolysis of 3 to propofol in alkaline phosphatase solution was extremely
rapid (t1/2 = 21 ± 3 sec) and the prodrug was readily converted to propofol in vivo in
rats.  The maximum plasma concentration (Cmax) of propofol, 3.0 ± 0.2 ?g/ml, was
reached within 2.1 ± 0.8 minutes (Tmax) after i.v. administration of 3. During
bioconversion, 3 releases acetaldehyde, a less toxic compound than the formaldehyde
released from the phosphonooxymethyl prodrug of propofol (Aquavan®), currently
undergoing clinical trials. The present study indicates that ethylidene phosphate
represents a potentially useful water-soluble prodrug structure suitable for i.v.
administration.
* Adapted with permission from: Kumpulainen H, Järvinen T, Mannila A, Leppänen J,
Nevalainen T, Mäntylä A, Vepsäläinen J, Rautio J. Synthesis, in vitro and in vivo
characterization of novel ethylide phosphate prodrug of propofol. Manuscript, submitted
for publication to the Journal of Medicinal Chemistry. Unpublished work copyright
2007 American Chemical Society.
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7.1 Introduction
Phosphates are probably the most extensively used water-soluble prodrugs for i.v.
administration. They have been synthesized to hydroxyl or amine functionalities of the
parent drug, either directly or via an oxymethyl spacer group. Oxymethyl spacers are
generally used to increase the space around the enzymatically cleavable bond
(phosphates, esters, carbonates) (Safadi et al. 1993, Varia et al. 1984) and they undergo
rapid spontaneous chemical hydrolysis after enzymatic hydrolysis of the promoiety.
One possible drawback of the oxymethyl linker structure is the systemic liberation of
the highly toxic compound, formaldehyde, in the body, which in addition to its toxicity,
may alter homeostasis within cells (such as induction of enzymes, metabolic switching
and cell proliferation) (Heck et al. 1990). An alternative strategy to achieve sufficiently
fast enzymatic hydrolysis rate and a more favourable safety profile of prodrugs is to use
an ethyloxy-spacer structure (which will be referred to as an ethylidene structure) that
liberates the much less toxic compound, acetaldehyde, from the prodrug structure
(Scheme 7.1). Although acetaldehyde is not fully harmless, since it can cause
gastrointestinal tract cancer particularly after long-term chronic alcohol consumption
(Seitz et al. 2005), it is substantially less toxic than formaldehyde.
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Scheme 7.1. The hydrolysis of ethylidene-linked phosphate prodrug of propofol to the
parent drug, promoiety and acetaldehyde.
The (acyloxy)alkyl group has been widely used to link an ester, a carbonate or a
carbamate promoiety to parent drugs containing a carboxylic acid functionality
(Beaumont et al. 2003), in fact many such prodrugs are even marketed (e.g. candesartan
cilexitil (Easthope and Jarvis 2002), cefuroxime axetil (Scott et al. 2001),
bacmecillinam (Josefsson et al. 1982)). By comparison, no ethylidene linked phosphate
prodrugs have been described in the literature. One possible reason is the challenge
involved in the synthesis of these compounds, in fact there are no techniques for the
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synthesis of ethylidene phosphates described in the literature (SciFinder Scholar,
Beilstein Crossfire). This represented our starting point; we were interested in
determining whether an ethylidene linked phosphate could be synthesized and whether
the ethylidene spacer could serve as a safe and biodegradable linker between the parent
drug and the phosphate promoiety.
For this study, we chose an anesthetic drug propofol as our model drug. Propofol
(Figure 7.1) is a widely used anesthetic with a rapid onset, a  short duration of action
and minimal side-effects (Baker and Naguib 2005). However, the extremely low water-
solubility, high lipophilicity, inherent emulsion instability, pain on injection and
hyperlipidemia on prolonged administration (Baker and Naguib 2005) are major
drawbacks, and thus, have lead to the development of water-soluble prodrugs. At least
two phosphate prodrugs of propofol have been described in the literature (Figure 7.1),
one with the phosphate group attached directly to the hydroxyl functionality of propofol
(Propofol Phosphate, PP) (Banaszczyk et al. 2002) and another with an oxymethyl
spacer between the parent drug and the phosphate promoiety (GPI 15715, Aquavan®)
(Gibiansky et al. 2005, Schywalsky et al. 2003, Struys et al. 2005). Both prodrugs
significantly enhance the water-solubility of propofol by many-fold, as would be
predicted from their structures. The enzymatic hydrolysis of GPI 15715 (Schywalsky et
al. 2003) is faster than that of PP (Banaszczyk et al. 2002), but on the other hand, PP
does not liberate the toxic formaldehyde as a breakdown product to the body. We hoped
to combine the properties of these two prodrugs and therefore we synthesized an
ethylidene linked phosphate prodrug 3 of propofol. Furthermore, we have extensively
characterized the ethylidene structure as a novel water-soluble phosphate prodrug
structure in vitro and in vivo in rats.
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Figure 7.1. The structures of propofol and its phosphate-, phosphonooxymethyl- (GPI
15715, Aquavan®) and ethylidene phosphate- (3) prodrugs.
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7.2 Results and Discussion
Synthesis. The phosphonooxymethyl derivative of propofol (5, GPI 15715) was
synthesized as previously described (Bonneville et al. 2003) from propofol with
bromochloromethane and phosphoric acid (Scheme 7.2) so that chemical stability
studies could be undertaken. The synthesis of ethylidene linked prodrug 3 was more
challenging. Our first attempt to develop a suitable synthesis route for ethylidene linked
prodrugs involved the method for the synthesis of 1-chloroethyl phosphates (see chapter
6). It was thought that 1-chloroethyl phosphates might possibly be used as starting
materials for the synthesis of ethylidene linked phosphate prodrugs. However, probably
because of the steric hindrance and the presence of a phenolic hydroxyl group which is
a good leaving group, the 1-chloroethyl phosphates did not react with propofol. The
second attempt was to use the same synthesis route to synthesize 1-chloroethyl ether of
propofol via vinyl ether, which could be further derivatized to phosphate. We found that
the only way to make vinyl ether of propofol was the use of tetravinyl tin and cuprous
acetate in an oxygen atmosphere (Blouin and Frenette 2001). The vinyl ether underwent
fast microwave-assisted conversion to 1-chloroethyl ether in the presence of HCl-gas at
100ºC within 10 minutes. This method was similar to that used to prepare vinyl
phosphates described previously (see chapter 6).
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Scheme 7.2. Reagents a) tetravinyltin, Cu(OAc)2, ACN b) HCl (g) / EtOAc, c) i.
tetrabutylammonium phosphate, TEA, ACN ii. NaOH, ACN d) bromochloromethane,
NaOH, THF, e) 85% phosphoric acid, TEA, ACN.
105
Since the ethylidene structure was found to be chemically acid-labile and since many
protecting groups of phosphates require acidic conditions for their removal, the
synthesis of an ethylidene phosphate was carried out without any protecting groups
being present. The synthesis was achieved by using tetrabutylammonium phosphate in
acetonitrile with an excess of triethylamine under dry and basic conditions in organic
solvent. The sodium salt 3 was obtained with the treatment of the product with sodium
hydroxide and the final product was purified with preparative HPLC. Since most of the
marketed (acyloxy) alkyl prodrugs are racemic mixtures, the enantiomers were not
separated but the racemic mixture was used in all assays which will be described.
Aqueous solubility. The aqueous solubility of propofol (130 ± 2 ?g/ml) was greatly
enhanced by the prodrug 3 since this compound has a solubility over 10 mg/ml (Table
7.1). The maximum solubility of 3 was not determined due to the small amount of
prodrug available. However, this limit was chosen since it has been estimated that in
general a drug needs to have a solubility of at least 10 mg/ml to be suitable for i.v.
administration (Stella 2006). Due to the fast and complete dissolution and limited
stability of 3, the shaking time was reduced to 1 hour from the conventional 72 hours.
Table 7.1. Half-lives of 3 and 5 in a buffer solution, half-life of 3 in alkaline
phosphatase solution and aqueous solubility of 3 and propofol in a buffer solution, all at
pH 7.4 (mean ± S.D.; n = at least 3).
a Not determined, b No degradation was observed after three weeks c Room temperature
Chemical stability. The chemical degradation rates of 3 and 5 were determined in 180
mM borate buffers at pH 7.4 at 37ºC and at room temperature. The chemical
degradation of both 3 and 5 followed first-order kinetics and the half-lives are presented
Cmpd Solubility
mg ml-1
Tris buffer
r.t.c,
Chemical
stability,  t1/2
Borate buffer
37ºC
Chemical
stability,  t1/2
Borate buffer
r.t.c
Enzymatic hydrolysis,
t1/2
Alkaline phosphatase,
37ºC
3 > 10 21.5 ± 0.8 h 5.2 ± 0.2 days 21 ± 3 sec
5 -a Stableb -a -a
Propofol 0.13 ± 0.002 -a -a -a
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in Table 7.1. The stability of 3 in buffer solution (t1/2 = 5.2 ± 0.2 days at r.t. and t1/2 =
21.5 ± 0.8 h at 37ºC, pH 7.4) was reasonably good if the drug were to be used for i.v.
administration, although the chemical degradation was significantly faster than that of 5
(no degradation was observed after three weeks). The faster chemical degradation of 3
compared to that of 5 is probably due to lower stability of the ethylidene acetal
compared to the methylene acetal. It is known that acetals with a good leaving group
(such as phenol) and a neighbouring carboxylic acid group undergo intramolecular
facilitated hydrolysis (Anderson and Fife 1973, Fife et al. 1996). Therefore, it can be
postulated that the acidic groups of phosphate facilitate the hydrolysis of 3 by forming
an oxocarbonium ion, which is internally greatly resonance-stabilized, leading to the
breaking of the C-O bond and the release of propofol (Scheme 7.3). Nonetheless, the
chemical stability of 3 is reasonable for i.v. use, though it may require the reconstitution
of the preparation prior to use.
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Scheme 7.3. The chemical hydrolysis of the ethylidene phosphate prodrug of propofol
(3).
Enzymatic degradation in vitro. The enzymatic hydrolysis of 3 was determined in
alkaline phosphatase solution. Only the half-life of 3 but not the exact amount of formed
propofol was determined due to the low solubility of propofol. The enzymatic
hydrolysis of 3 to propofol was extremely rapid with a half-life of approximately 20
seconds. This fast enzymatic hydrolysis of 3 suggests that ethylidene linked prodrugs
act in a similar manner as conventional phosphate and phosphonooxymethyl prodrugs
and release the parent drug rapidly via the action of alkaline phosphatases.
Bioconversion of ethylidene phosphate to propofol in vivo. The conversion of 3 to
propofol was demonstrated in vivo in rats after a single i.v. bolus administration. One
group of three adult male Wistar rats received a single bolus dose of 10 mg/kg of
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propofol (0.056 mmol/kg) and another group of three rats received 19.4 mg/kg of 3
(0.056 mmol/kg). The plasma concentration of propofol was determined from whole
blood samples using thymol as an internal standard with the method described
previously in the literature (Yeganeh and Ramzan 1997). Only the amount of propofol,
not the amount of prodrug, was determined and compared between the groups. The
concentration curves of propofol after administration of 3 and propofol are presented in
Figure 7.2, in which each line shows the values of individual rats. After administration
of prodrug or propofol the pharmacokinetics revealed a fast initial decline and a slower
elimination phase and these were best described by a two-compartmental model. The
levels of propofol in whole blood (?g/ml) and the pharmacokinetic parameters (Tmax,
Cmax) were determined using the above mentioned simulation and are shown in Table
7.2. The pharmacokinetic parameters of GPI 15715 and propofol phosphate are gathered
from the publications of Schywalski et al. 2003 and Banaszczyk et al. 2002,
respectively.
Figure 7.2. Propofol levels after single i.v. bolus dose of A) 3 (19.4 mg/kg) and B)
propofol (10 mg/kg) into rats (n = 3). Each line shows the measured values of one rat.
Prodrug 3 was readily converted to propofol in each rat after i.v. administration. The
maximum plasma concentration (Cmax) of propofol, 3.0 ± 0.2 ?g/ml, was reached within
2.1 ± 0.8 minutes (Tmax) after the administration of 3. Rats that received 3 were
uncoordinated and had difficulties in maintaining their balance. In contrast, the dose of
10 mg/kg of propofol was sufficient to evoke sedation which occurred at approximately
13 seconds after the i.v. bolus. The difference between the concentrations of propofol
after equimolar administration of 3 and propofol is similar to the results reported for
GPI 15715 (Schywalsky et al. 2003) and is probably due to formulation-dependent
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pharmacokinetics of propofol. A lipid-free formulation of propofol has a greater volume
of distribution and a greater elimination clearance, but a similar terminal half-life when
compared to the oil-in-water formulation (Dutta and Ebling 1998b). The lipid-free
formulation of propofol has also been shown to have a larger distribution in the lungs
compared to the oil-in-water formulation and the slow release of propofol from the
lungs leads to decreased concentrations in the circulation (Dutta and Ebling 1998a). 3,
like GPI 15715 (Schywalsky et al. 2003), probably acts like the lipid-free formulation,
releasing the lower concentrations of propofol to the circulation than is seen after
equimolar administration of propofol.
Table 7.2. Estimated pharmacokinetic parameters (mean ± SD) of propofol after single
i.v. bolus dose of 3 (19.4 mg/kg, 0.056 mmol/kg) and propofol (10 mg/kg, 0.056
mmol/kg) into rats (n = 3) and pharmacokinetic parameters of GPI 15715 and PP from
the literature.
Cmpd 3 Propofol GPI 15715a Propofol
phosphateb
Dose 19.4 mg /kg
(0.056
mmol/kg)
10 mg / kg
(0.056 mmol/kg)
40 mg /kg
(0.120
mmol/kg)
130 mg /kg
(0.499
mmol/kg)
Cmax (?g/ml) 3.0 ± 0.2 14.3 ± 1.8 7.1 ± 1.6 9.6 ± 2.1
Tmax (min) 2.1 ± 0.8 -c 3.7 ± 0.2 7.3 ± 3.8
Cmax = maximum concentration of propofol, Tmax = time to maximum concentration of propofol
a From Schywalsky et al 2003, b From Banaszczyk et al 2002, c After i.v. bolus Tmax = 0 min
When compared to GPI 15715, the maximum concentration of propofol, 3.0 ± 0.2
?g/ml after administration of 3 (19.4 mg/kg, 0.056 mmol/kg), is approximately half of
the concentration achieved after administration of GPI 15715 with over double the dose
(7.1 ± 1.6 ?g/ml after 40 mg/kg, 0.120 mmol/kg) (Schywalsky et al. 2003). Since the
maximum concentration of propofol was also reached at approximately the same time
(2.1 ± 0.8 and 3.7 ± 0.2 min for 3 and GPI 15715, respectively), we conclude that the
bioconversion of 3 to propofol is as effective as that of GPI 15715. The bioconversion
of 3 to propofol was much faster and more effective, when compared to PP (Banaszczyk
et al. 2002) which has a Tmax of 7.3 ± 3.8 minutes and a Cmax of 9.6 ± 2.1 ?g/ml after i.v.
administration of PP with a dose as great as 130 mg/kg (0.499 mmol/kg).
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The purpose of this study was to confirm the bioconversion of 3 to propofol in vivo,
not to evoke complete sedation in the rats. The sedated behaviour of rats demonstrated
that propofol had been released from 3, but larger doses would be needed to achieve
complete sedation. This effect is similar to that reported earlier in case of GPI 15715
(Schywalsky et al. 2003). Even though the pharmacokinetic parameters are not truly
comparable between different studies due to the dose-dependent onset of the action and
recovery of propofol from prodrugs, this study indicates that 3 is bioconverted to
propofol in a similar manner as the phosphonooxymethyl prodrug GPI 15715.
7.3 Conclusions
A novel ethylidene-linked phosphate prodrug of propofol (3) has been shown to
increase the water-solubility of the poorly water-soluble drug propofol. The chemical
stability of 3 is sufficient for i.v. administration, but is limited due to the presence of the
more labile ethylidene acetal. The enzymatic release of propofol from 3 is rapid both in
vitro with alkaline phosphatase solution and in vivo in rats. The bioconversion of 3 to
propofol is similar to that of GPI 15715, the phosphonooxymethyl prodrug of propofol,
and much faster when compared to propofol phosphate.  In this study, no evidence was
observed of any abnormal pharmacokinetics that could be explained by chirality.
However, since enantiomers often have different pharmaceutical and pharmacokinetic
profiles (Hutt and Tan 1996) and also differences in binding to serum albumin (Chuang
and Otagiri 2006), in the future it might be worthwhile to separate the enantiomers and
to evaluate their individual  pharmaceutical and pharmacokinetic behaviours. This is not
a unique problem of 3, it applies to all ethyloxy prodrugs, in fact most of the (acyloxy)
alkyl prodrugs are marketed as racemic mixtures.
The results of the present study provide clear evidence that the ethylidene linker is
suitable for preparing phosphate prodrugs designed for i.v. administration. This novel
prodrug structure combines the properties of previously described phosphate and
phosphonooxymethyl prodrugs i.e. there is as efficient bioconversion to propofol as can
be attained with the phosphonooxymethyl prodrug, but there is no systemic release of
formaldehyde after administration of the phosphate prodrug. Further studies with
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different model drugs containing hydroxyl and amine functionalities are ongoing in
order to explore the overall versatility of this novel phosphate prodrug structure.
7.4 Methods
2,6-Diisopropyl-2-vinyloxy-benzene 1. Anhydrous copper (II) acetate (3.67 g, 20.19
mmol) was added to a solution of 2,6-diisopropyl phenol (3 g, 16.83 mmol) in dry
acetonitrile. The reaction flask was rinsed with O2. Tetravinyltin (3.74 g, 16.48 mmol)
was added to the reaction mixture via a syringe and the reaction was stirred for 1 hour at
room temperature. O2-bubbling was replaced by a O2-balloon and reaction was stirred at
60ºC for 16 h. The resulting brown mixture was poured into a 25 % NH4OAc-solution
(30 ml) and stirred for 15 min. The reaction was extracted with Et2O (150 ml). The
organic layer was washed with saturated brine (2 × 40 ml), dried over Na2SO4 and
evaporated to dryness. Flash chromatography on SiO2 (2 % ethylacetate in petrol ether)
gave 1 as a colorless oil (1.34 g, 6.56 mmol, 39 %). 1H NMR (CDCl3) ? 7.18-7.10 (3H,
m), 6.60 (1H, dd, J = 14.0 Hz and 6.5 Hz), 4.15-4.08 (2H, m), 3.18 (2H, h, J = 6.9 Hz),
1.19 (12 H, d, J = 6.9 Hz).
2-(1-Chloro-ethoxy)-1,3-diisopropyl-benzene 2. Ethyl acetate was saturated with
dry HCl-gas by bubbling gaseous HCl through the solution for 10 min. 2 (1.04 g, 5.1
mmol) was dissolved in 10 ml of HCl-saturated ethyl acetate. The mixture was heated in
a microwave-oven at 100ºC at 5 bar for 10 min and evaporated to dryness. The next
reaction was continued immediately without any further purification.
Phosphoric acid mono-[1-(2,6-diisopropyl-phenoxy)-ethyl] ester disodium salt 3.
To a solution of tetrabutylammonium phosphate (0.4 M in acetonitrile, 30 ml, 12 mmol)
was added 2 (5.1 mmol, theoretical maximum yield) in triethylamine (5 ml, 36 mmol)
under argon. The reaction mixture was stirred for 18 hours and the solvents were
evaporated. 30 ml of water was added and the residue was extracted with diethyl ether
(3 × 50 ml). Solvents were evaporated, 10 ml of acetonitrile was added and the pH of
the mixture was adjusted to 11 with saturated NaOH. After stirring for 10 minutes, the
solvents were evaporated, the residue was purified with preparative HPLC on a reversed
phase Kromasil 100 Å (C8) column by gradient elution using water and acetonitrile (40-
80 % ACN)  as the eluent and lyophilized to obtain 3 as a white solid (494 mg, 1,43
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mmol, 28 %). 1H NMR (D2O) d 7.29-7.22 (3H, M), 5.54 (1H, q, J = 5.1 Hz), 3.42 (2H,
m), 1.66 (3H, d, J = 5.1 Hz), 1.21 (12 H, t, J = 6.9 Hz). 13C NMR (D2O) d 152.30,
146.45, 128.57, 127.08, 103.04, 29.28, 26.03 (d, J = 15.2 Hz), 24.97. 31P NMR (D2O)
d 0.03. ESI-MS: 301.3 (M - 2*Na + 1). Anal. Calcd for C14H21Na2O5P · 0.7 H2O: C,
46.85; H, 6.29. Found: C, 46.79; H, 6.29.
2-Chloromethoxy-1,3-diisopropyl-benzene 4. Sodium hydroxide pellets (1.2 g, 30.0
mmol) and bromochloromethane (28.7 ml, 57.1 g, 441 mmol) were added to a solution
of 2,6-diisopropyl phenol (2.7 g, 15.2 mmol) in dry tetrahydrofuran under nitrogen. The
reaction mixture was heated at 64ºC for two hours, allowed to cool to room temperature
and filtered. The filtrate was evaporated to dryness to obtain 4 as a yellowish oil (3.2 g,
14.1 mmol, 93 %). 4 was used in the next reaction without any further purification. 1H
NMR (CDCl3) d 7.20-7.09 (3H, m), 5.75 (2H, s), 3.35 (2H, m), 1.22 (12 H, d, J = 6.9
Hz).
 Phosphoric acid mono-(2,6-diisopropyl-phenoxymethyl) ester disodium salt 5.
To a solution of triethylamine (13.03 ml, 9.46 g, 93.5 mmol) and 85 % phosphoric acid
(5.86 ml, 9.87 g, 101 mmol) was added 4 (3.2 g, 14.1 mmol) and the reaction mixture
was heated at 64ºC for 2.5 hours. The solvents were evaporated, 100 ml of water was
added to the residue and the pH of the mixture was adjusted to 1.5 with 6 M HCl. The
aqueous solution was extracted with diethyl ether (3 × 50 ml), washed with brine and
evaporated to dryness. 50 ml of water was added to the residue and pH was adjusted to
9 with saturated NaOH-solution. The mixture was washed with toluene (2 × 30 ml) and
concentrated under reduced pressure to half of the volume. 100 ml of isopropanol was
added, the mixture was frozen, allowed to warm to 0ºC, filtered and dried in a vacuum
oven to obtain 5 as a white solid (0.87 g, 3.0 mmol, 21 %) 1H NMR (D2O) d  7.32-7.24
(3H, m), 5.27 (2H, d, J = 7.5 Hz), 3.46 (2H, m), 1.22 (12 H, d, J = 6.9 Hz).  13C NMR
(D2O) 152.96, 145.90, 128.63, 127.03, 96.11, 28.97, 25.95. 31P NMR (D2O) d 2.02.
ESI-MS: 287.1 (M - 2×Na + 1). Anal. Calcd for C13H19Na2O5P · 0.2 H2O: C, 46.49; H,
5.82. Found: C, 46.12; H, 5.82.
HPLC analysis. HPLC analysis of 3, 5 and propofol was performed using an Agilent
Technologies 1100 series gradient RP-HPLC system with UV detection (220 nm) and
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for rat whole blood samples the fluorescence detection (Ex = 276 nm, Em = 310). The
HPLC system consisted of Agilent 1100 Series Binary Pump, 1100 Series Autosampler,
1100 Series Micro Vacuum Degasser, 1100 Series Thermostated Column Compartment,
1100 Series Fluorescence Detector, HP 1050 Variable Wavelenght Detector, 1100
Series Control Module and a Zorbax Eclipse XDB-C8 (4.6 mm × 150 mm, 5 ?m)
analytical column (Agilent Technologies Inc., Little Falls, Wilmington, DE, USA).
Loop injection volume was 20 ?l. The isocratic elution was performed by using a
mobile phase consisting of 90 % (v/v) acetonitrile and 10 mM tetrabutylammonium
dihydrogen phosphate at a ratio of 65:35 at a flow rate of 1.0 ml/min at 30ºC.
Animal treatments. Adult male Wistar rats weighing 250 ± 5 g were anesthetized
with ketamine (90 mg/kg, i.p.) and xylazine (8 mg/kg, i.p.). The right jugular vein was
exposed aseptically as described by Waynforth and Flecnell (Waynforth and Fleckell
1994), and cannulated with a PE-50 catheter filled with 100 IE/ml heparin. The catheter
was exteriorised through a small incision made in the neck. The rats were allowed to
recover until the following day.
The drug solutions were administered to the conscious rats as 30-second i.v. injections
(including the rinsing of the catheter with 0.9 % NaCl). For the determination of
propofol, venous blood samples of 200 ?l were collected immediately before and 1, 2,
4, 6, 10 and 30 min after the i.v. bolus administration, mixed with 20 ?l of 3 % EDTA
in 0.7 % NaCl-solution and frozen immediately. The drawn blood volume was replaced
with 0.9 % NaCl.
Rat blood sample preparations. For the assay of propofol in rat whole blood samples,
the red blood cells were lysed with a total of three freeze/thaw cycles. 10 ?l of 90 ?g/ml
thymol as internal standard was added to 100 ?l of lysed whole blood, then 250 ?l of
acetonitrile was added to precipitate proteins and the samples were centrifuged for 3 min
at 12 000 rpm. The supernatant was injected directly into the HPLC column. The quantity
of propofol was determined using external, spiked standards of lysed whole blood and the
concentration was estimated based on peak-area ratio of propofol to the internal standard
(thymol). All concentration curves and pharmacokinetic parameters (Tmax, Cmax) after i.v.
administration for each animal were calculated by standard pharmacokinetic methods
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using WinNonlin Nonlinear Estimation Program, Professional version 5.0.1 (Pharsight
Corporation).
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8 SYNTHESIS, IN VITRO AND IN VIVO CHARACTERIZATION OF DIESTER
PHOSPHATE PRODRUGS*
Abstract: Monomethyl ester derivatives of phosphate and phosphonooxymethyl
prodrugs of propofol were synthesized and evaluated in vitro and in vivo as possible
prodrug structures for enhanced lipophilicity and permeability compared to the
corresponding phosphate prodrug and for enhanced water-solubility compared to the
parent drug. However, neither of the monomethylphosphates was enzymatically cleaved
in vitro in solutions of alkaline phosphatase, phosphodiesterase or rat liver homogenate
in vivo in rat. Thus, the monoalkyl esters of phosphates do not seem to be suitable for
use as potential bioreversible prodrug structures.
*  Unpublished results
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8.1 Introduction
The enzymatic hydrolysis of orally administered phosphate prodrugs to the parent drug
takes place at the intestinal brush border by alkaline phosphatases (Heimbach et al.
2007). The bioconversion occurs just prior to the absorption, after which the more
lipophilic parent drug is absorbed through the intestinal membrane. Due to the presence
of two negative charges, the phosphate prodrug itself is too hydrophilic to pass through
the biological membrane by passive diffusion. If the bioconversion of the prodrug to the
parent drug is not complete or if the bioconversion rate is not fast enough, the
absorption, and thus, the bioavailability of the parent drug will limited. In addition, poor
permeability or precipitation of the cleaved parent drug at the surface of the intestinal
membranes may limit the absorption of the parent drug (Heimbach et al. 2003).
Phosphate diesters with one free negative charge in the phosphate structure might
serve as prodrugs with enhanced aqueous solubility compared to the parent drug but
greater lipophilicity and thus better permeability compared to the corresponding
phosphate prodrug. These prodrugs may not be substrates of alkaline phosphatases
themselves (McComb et al. 1979), but they may be hydrolyzed first to phosphates by a
group of enzymes called phosphodiesterases (Jeon et al. 2005, Khan et al. 2005),
followed by the enzymatic activation by alkaline phosphatases. Phosphodiesterases
(PDE) are enzymes that hydrolyze cyclic nucleotides to monophosphates in the body
(Jeon et al. 2005). Inhibitors of PDEs are well-known (e.g. sildenafil (Viagra®), an
inhibitor of PDE5 (Goldstein et al. 2002)), but the use of phosphodiesterases in the
design of prodrug bioactivation has been studied to a lesser extent. The literature
contains only a few descriptions of diester phosphate prodrugs (Hadimani et al. 2003,
Rosowsky et al. 1982) cleaved by phosphodiesterases to improve the passive uptake
through membranes, but there has been no evaluation of diester phosphates as prodrugs
with the exception of some nucleotide-type structures.
In order to find out if diester phosphates would be useful prodrug structures, we chose
propofol to represent a model drug. In this study we synthesized phosphate (1, Figure
8.1) and phosphonooxymethyl (4) prodrugs of propofol as reference compounds and
monomethyl esters of these phosphates (2 and 7). We evaluated the suitability of these
structures as prodrug structures in vitro and in vivo. The enzymatic release of the active
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drug from the prodrugs was studied in vitro in solutions of alkaline phosphatase,
phosphodiesterase and rat liver homogenate and finally in vivo in rats.
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Figure 8.1.  The structures of propofol and its phosphate (PP, 1)-,
phosphonooxymethyl- (GPI 15715, Aquavan®, 4) and their monomethyl ester
derivatives (2 and 7).
8.2 Results and Discussion
Synthesis. The propofol phosphate 3 was synthesized by a standard method from the
propofol and POCl3. The monomethyl phosphate 2 was synthesized from the
dichlorophosphoryl intermediate by adding an equivalent of methanol, following the
addition of water to hydrolyze the remaining chloride (Scheme 8.1). Due to the mixture
of byproducts (including dimethyl phosphate and free phosphates), which required
several HPLC-purification steps to obtain analytically pure products, the yield of this
synthesis was not very high. However, due to the low costs of the reagents and small
number of reaction steps, it was felt worthwhile to use this reaction route instead of
synthesizing dimethyl phosphate and then attempting to selectively remove one of the
methyl groups.
The phosphonooxymethyl derivative of propofol (4) was synthesized as previously
described from propofol with bromochloromethane and phosphoric acid (Bonneville et
al. 2003). A similar synthesis route was used for the synthesis of the monomethyl ester 7.
The chloromethoxy derivative of propofol (3) was coupled with dimethyl phosphate 5 to
obtain dimethyl phosphonooxymethyl propofol (6) with reasonably good yields, followed
by the selective removal of one of the methyl groups. This synthesis, as well as the
synthesis of dimethyl phosphate 5 from trimethyl phosphate, was carried out in a
microwave oven using sodium iodide in acetone for 10-20 min at 100ºC. In particular, the
synthesis of 5 proved to be a convenient way to make dimethyl phosphates, when
compared to the previously described method with tetra-n-butylammonium hydroxide
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and 24 hours of refluxing (Phan and Poulter 2001). The method described now also lacks
the tetra-n-butylammonium counter ion, which is often difficult to remove.
The synthesis product 7 contained some impurities that made the crude product
extremely difficult to purify. Nonetheless, three consecutive purifications by preparative
HPLC yielded approximately 80 % pure product, which was then used for the in vitro and
in vivo assays described below. Thus, the elemental analysis and MS-spectras were not
obtained.
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Scheme 8.1. Reagents: a)POCl3, n-BuLi, Et2O, b) MeOH, TEA, c) H2O, d) BrCH2Cl,
NaOH, THF, e) 85% phosphoric acid, TEA, ACN, NaOH, f) 5, TEA g) NaI, acetone.
Enzymatic degradation. The enzymatic degradation of prodrugs was studied in
solutions of alkaline phosphatase, phosphodiesterase I and in rat liver homogenate, in
which both of the monomethyl ester prodrugs 2 and 7 were stable. The stability in
alkaline phosphatase solution was anticipated since it is known that diesters do not serve
as substrates for alkaline phosphatase (McComb et al. 1979). However, the stability in
phosphodiesterase and liver homogenate solutions was somewhat surprising, since
phosphodiesterase is known to be able to break O-C bonds of diester phosphates. One
possible reason for the stability might be the small sizes of both the methyl group and
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propofol. Endogenous PDEs degrade cyclic adenosine and guanosine monophosphates,
which are much larger in their molecular size and also have a larger size of the ester
group. The PDEs may also require the presence of a nucleotide structure in its substrate
before they are able to degrade the ester bond.
Conversion of monomethyl phosphate prodrugs to propofol in vivo. In order to
confirm that the results obtained from the in vitro tests would reflect the in vivo situation,
the bioconversion of prodrugs to propofol was studied in rats after a single i.v. bolus
administration by the method described in chapter 7. One male Wistar rat received a
single bolus dose of 21.8 mg/kg of 2 (0.056 mmol/kg) and another rat received 16.9
mg/kg of 7 (0.056 mmol/kg). Propofol was determined from the rat whole blood samples.
The results from the in vivo experiment confirmed the results from in vitro studies, and
no propofol was obtained in the rat whole blood samples during 30 min experiment. In
addition, no changes in the behaviour of the rat were observed during experiment. This
seemed to be convincing proof that propofol was not released from the prodrug structure.
Chemical stability, aqueous solubility and lipophilicity. Due to the unpromising
results of the in vitro and in vivo enzymatic cleavability studies, the chemical stability,
lipophilicity and aqueous solubility experiments were not clarified. However, using the
retention times in HPLC method as a rough indicator, it can be estimated that these
diesters are more water-soluble than propofol, but more lipophilic than the free
phosphates (retention times for free phosphates around 3 min, for monomethyl
phosphates around 4 min and for propofol 9.1 min). The chemical stability of the diesters
seems to be limited, as the free phosphates were formed during storage of the stock
solutions.
8.3 Conclusions
The monomethyl ester derivatives of propofol phosphate were studied as possible
prodrug structures with the aim of creating compounds with enhanced lipophilicity and
permeability compared to the corresponding phosphate prodrugs and better water-
solubility compared to the parent drug. However, neither monomethylphosphate of
propofol (2) nor monomethyl phosphonooxymethyl propofol (7) was enzymatically
cleaved in vitro in solutions of alkaline phosphatase, phosphodiesterase or rat liver
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homogenate or in vivo in rat. The probable reason for high enzymatic stability is the
structure of propofol. The small sizes of both the methyl group and propofol differ from
the natural substrates of PDEs (nucleotides such as cyclic adenosine and guanosine
monophosphates). However, these prodrug structures may be potentially useful for
compounds with a nucleotide-type structure and larger ester groups but this speculation
will need to be studied in future experiments.
8.4 Methods
Phosphoric acid mono-(2,6-diisopropyl-phenyl) ester 1. To a solution of 2,6-
diisopropylphenol (2.0 g, 11.2 mmol) in diethylether (20 ml) was added n-butyl lithium
(6.9 mL, 11.3 mmol) at -30 °C under argon over 10 min. The mixture was stirred for 30
min at -30 °C and then for 30 min at r.t. The reaction mixture was then slowly added to
a solution of phosphorous oxychloride (1.1 ml, 12.0 mmol) in 20 ml of diethylether at -
30 °C. The reaction mixture was allowed to reach the room temperature and stirred at
r.t. for 21 h. 10 ml of distilled water was added to the reaction mixture and the mixture
was stirred for an additional 1 hour. Sodium hydroxide (70 ml, 1 M) was added and the
reaction mixture washed three times with hexane. The pH of the aqueous phase was
adjusted to 2 with hydrochloric acid (3 M) and washed with diethyl ether (3 × 50 ml).
The combined organic phases were dried over Na2SO4 and evaporated to dryness. The
residue was purified with Shimadzu preparative HPLC on reversed phase Supelco PLC-
8 column using a 60:40 mixture of acetonitrile and trifluoroacetic acid (0.1 % in water)
as eluent and lyophilized to dryness to yield 1 as a white solid (0.41 g, 1.6 mmol, 14 %).
1H NMR (D2O) d 7.14 (1H, t, 7.5 Hz), 7.09 (2H, d, 7.5 Hz), 3.32 (2H, sep, J = 6.8 Hz),
1.13 (12H, d, J = 6.8 Hz).  13C NMR (CDCl3) 145.7 (d, J = 8.9 Hz), 140.54 (d, J = 3.4
Hz), 126.17 (d, J = 1.8 Hz), 124.40, 27.04, 23.15. 31P NMR (D2O) d -1.96. ESI-MS:
257.4 (M - 1). Anal. Calcd for C12H19O4P · 0.1 H2O: C, 55.42; H, 7.44. Found: C, 55.31;
H, 7.36.
Phosphoric acid 2,6-diisopropyl-phenyl ester methyl ester 2. To a solution of 2,6-
diisopropylphenol (2.0 g, 11.2 mmol) in diethylether (20 ml) was added n-butyl lithium
(6.9 mL, 11.3 mmol) at -30 °C under argon over 10 min. The mixture was stirred for 30
min at -30 °C and then for 30 min at r.t. The reaction mixture was then slowly added to
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a solution of phosphorous oxychloride (1.1 ml, 12.0 mmol) in 20 ml of diethylether at
-30 °C. The reaction mixture was allowed to reach the room temperature and stirred at
rt. After 27 h, methanol (0.5 ml, 12.3 mmol), triethylamine (1.7 ml, 12.2 mmol) and
diethylether (20 ml) were added to the reaction mixture. The reaction mixture was
stirred at r.t. for 70 h, after which distilled water (10 ml) was added. The mixture was
stirred for an additional 1.5 hours, washed three times with hydrochloric acid (0.5 M)
and extracted with diethylether (3 × 50 ml). The combined organic phases were dried
over Na2SO4 and evaporated to dryness. The residue was purified with Shimadzu
preparative HPLC on reversed phase Supelco PLC-8 column using a 60:40 mixture of
acetonitrile and trifluoroacetic acid (0.1 % in water) as eluent and lyophilized to dryness
to yield 2 as a white solid (1.11 g, 4.0 mmol, 36 %). 1H NMR (D2O) d  7.16-7.03 (3H,
m), 3.74 (3H, d, J = 11.5 Hz), 3.42 (2H, sep, J = 6.8 Hz), 1.18 (12H, d, J = 6.8 Hz). 13C
NMR (D2O) 147.08 (d, J = 8.5 Hz), 141.31 (d, J = 2.4 Hz), 125.17, 124.08, 153.22 (d, J
= 6.2 Hz), 26.61, 23.01. 31P NMR (D2O) d -2.49. ESI-MS: 271.5 (M - 1). Anal. Calcd
for C13H21O4P · 0.1 H2O: C, 56.97; H, 7.80. Found: C, 56.90; H, 7.71.
2-Chloromethoxy-1,3-diisopropyl-benzene 3. To a solution of 2,6-diisopropyl
phenol (2.7 g, 15.2 mmol) in dry tetrahydrofuran sodium hydroxide pellets (1.2 g, 30.0
mmol) and bromochloromethane (28.7 ml, 57.1 g, 441 mmol) were added under
nitrogen. The reaction mixture was heated at 64ºC for two hours, allowed to cool to
room temperature and filtered. The filtrate was evaporated to dryness to obtain 3 as a
yellowish oil (3.2 g, 14.1 mmol, 93 %). 3 was used in the next reaction without any
further purification. 1H NMR (CDCl3) d 7.20-7.09 (3H, m), 5.75 (2H, s), 3.35 (2H, sep,
J = 6.9 Hz), 1.22 (12 H, d, J = 6.9 Hz).
 Phosphoric acid mono-(2,6-diisopropyl-phenoxymethyl) ester disodium salt 4.
To a solution of triethylamine (13.03 ml, 9.46 g, 93.5 mmol) and 85 % phosphoric acid
(5.86 ml, 9.87 g, 101 mmol) was added 4 (3.2 g, 14.1 mmol) and the reaction mixture
was heated at 64ºC for 2.5 hours. Solvents were evaporated, 100 ml of water was added
to the residue and the pH of the mixture was adjusted to 1.5 with 6 M HCl. The aqueous
solution was extracted with diethylether (3 × 50 ml), washed with brine and evaporated
to dryness. 50 ml of water was added to the residue and the pH was adjusted to 9 with
saturated NaOH-solution. The mixture was washed with toluene (2 × 30 ml) and
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concentrated under reduced pressure to half of the volume. 100 ml of isopropanol was
added, the mixture was frozen, allowed to warm to 0ºC, filtered and dried in vacuum
oven to obtain 4 as a white solid (0.87 g, 3.0 mmol, 21 %) 1H NMR (D2O) d  7.32-7.24
(3H, m), 5.27 (2H, d, J = 7.5 Hz), 3.46 (2H, sep, J = 6.9 Hz), 1.22 (12 H, d, J = 6.9 Hz).
13C NMR (CDCl3) 151.61, 141.99, 125.54, 124.16, 94.07 (J = 2.9 Hz), 26.72, 24.06. 31P
NMR (D2O) d 2.02. ESI-MS: 287.1 (M - 2×Na + 1). Anal. Calcd for C13H19Na2O5P ·
0.2 H2O: C, 46.49; H, 5.82. Found: C, 46.12; H, 5.82.
Phosphoric acid dimethyl ester 5. To a solution of trimethyl phosphate (1.7 ml,
14.6 mmol) in acetone (15 ml) NaI (2.18 g, 14.6 mmol) was added. The reaction was
heated for 20 min at 100°C in a microwave oven. A white precipitate was collected and
dried in a vacuum oven to obtain 5 as a white solid (2.03 g, contains solvent). 5 was
used to the next reaction without any further purification.
Phosphoric acid 2,6-diisopropyl-phenoxymethyl ester dimethyl ester 6.  To a
solution of 3 (1.04 g, 4.6 mmol) in acetonitrile (60 ml) 5 (1.96 g, 13.2 mmol) and
triethylamine (4 ml, 28.6 mmol) were added. After stirring at 50-55 °C for 17 hours, the
reaction mixture was evaporated to dryness and dissolved in water. The pH of the
aqueous mixture was adjusted to 1.5 with HCl (3 M), extracted with diethyl ether (3 ×
50 ml), dried over Na2SO4 and evaporated to dryness to yield 6 as white solid (1.20 g,
3.79 mmol, 82 %, unpurified). 6 was used in the next reaction without any further
purification.
Phosphoric acid 2,6-diisopropyl-phenoxymethyl ester methyl ester 7. To a
solution of 6 (1.05 g, 3.3 mmol) in acetone (20 ml) NaI (0.28 g, 1.86 mmol) was added.
The reaction was heated for 10 min at 100°C in a microwave oven and the solvents
were evaporated. The residue was dissolved in water. The pH of the aqueous mixture
was adjusted to 1 with HCl (3 M), extracted with diethyl ether (3 × 50 ml), dried over
Na2SO4 and evaporated to dryness. The residue was purified with a Shimadzu
preparative HPLC on a reversed phase Supelco PLC-8 column using a 60:40 mixture of
acetonitrile and trifluoroacetic acid (0.1 % in water) as eluent and lyophilized to dryness
to yield 2 as á white solid (0.2 g, 0.7 mmol, 21 %). 1H NMR (CDCl3) d 7.14-7.06 (3H,
m), 5.43 (2H, d, J = 9.95 Hz), 3.68 (3H, d, J = 11.45), 3.34 (2H, sep, J = 6.85 Hz), 1.20
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(12H, d, J = 6.85 Hz). 13C NMR (CDCl3) 151.37, 141.80, 125.84, 124.29, 94.35 (J = 4.0
Hz), 54.29 (J = 5.7 Hz), 26.81, 24.02. 31P NMR (CDCl3) d 0.18.
HPLC analysis. HPLC analysis of prodrugs and propofol from the in vitro
experiments was performed using an analytical HPLC system, which consisted of a
Merck Hitachi (Hitachi Ltd., Tokyo, Japan) L-7100 pump, D-7000 interface module, L-
7455 diode-array UV detector (190-800 nm, set at 220 nm), and L-7250 programmable
autosampler. Rat whole blood samples were analyzed using an analytical Agilent
Technologies 1100 series gradient RP-HPLC system consisted of Agilent 1100 Series
Binary Pump, 1100 Series Autosampler, 1100 Series Micro Vacuum Degasser, 1100
Series Thermostated Column Compartment, 1100 Series Fluorescence Detector (Ex =
276 nm, Em = 310), HP 1050 Variable Wavelength Detector, 1100 Series Control
Module and a Zorbax Eclipse XDB-C8 (4.6 mm × 150 mm, 5 ?m) analytical column
(Agilent Technologies Inc., Little Falls, Wilmington, DE, USA). The loop injection
volume was 20 ?l. The isocratic elution was performed by using a mobile phase
consisting of 90 % (v/v) acetonitrile and 10 mM tetrabutylammonium dihydrogen
phosphate at a ratio of 65:35 at a flow rate of 1.0 ml/min at 30ºC.
Animal treatments. Rats were anesthetized with ketamine (90 mg/kg, i.p.) and
xylazine (8 mg/kg, i.p.). The right jugular vein was exposed aseptically as described by
Waynforth and Flecnell, (Waynforth and Fleckell 1994) and cannulated with a PE-50
catheter filled with 100 IE/ml heparin. The catheter was exteriorised through a small
incision made in the neck. The rats were allowed to recover till the following day.
The drug solutions were administered to conscious rats as 30-second intravenous
injections (including the rinsing of the catheter with 0.9 % NaCl). For the determination
of propofol, venous blood samples of 200 ?l of each were collected immediately before
and 1, 2, 4, 6, 10 and 30 min after the i.v. bolus administration, mixed with 20 ?l of 3 %
EDTA in 0.7 % NaCl-solution and frozen immediately. The drawn blood volume was
substituted by 0.9 % NaCl.
Rat blood sample preparations. For the assay of propofol in rat whole blood
samples, the red blood cells were lysed by a total of three freeze/thaw cycles. 10 ?l of
90 ?g/ml thymol as internal standard was added to 100 ?l of lysed whole blood. 250 ?l
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of acetonitrile was added to precipitate proteins and the samples were centrifuged for 3
min at 12 000 rpm. The supernatant was injected directly into the HPLC column.
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9 GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Prodrug technology has become an integral part of the drug discovery and development
process and at present a significant proportion of marketed drugs are prodrugs.
However, systematic basic research focusing on the discovery of novel promoieties for
different functional groups and pharmaceutical / clinical applications is still needed in
order to expand the applicability of prodrugs. In addition, as the information about
numerous enzymes, transporters and their substrates is expanding, the possibilities are
increasing to utilize these proteins as activators or as uptake transporters of prodrugs
through the intestinal membranes or into the specific tissues / organs.
A successful prodrug project requires intensive collaboration between medicinal
chemists, pharmacokinetists, pharmacologists, toxicologists and formulation scientists
in the drug design and development process. If a potential lead compound has some
characteristic that limits its use as a drug, these teams should collaborate on the
selection of an appropriate prodrug structure. The most important step is to identify the
property of the parent drug that needs improvement. These properties may include the
poor oral bioavailability resulting from poor aqueous solubility, poor lipophilicity,
extensive first-pass metabolism or acting as a substrate for the efflux proteins on the
intestinal membranes or in other organs (such as the brain), limiting the bioavailability
and transport of the parent drug. Other important factors affecting the selection of the
prodrug structure are the presence of functional groups amenable to prodrug
derivatization, the desired mechanism and location of the bioactivation pathway, the
route of administration, the chemical environment of the functional group in question
and the nontoxicity of the promoiety. In addition, this study also highlighted the
significance of the selection of an appropriate model compound for the studies of novel
prodrug structures.
Academic research aims at producing reliable and objective basic studies that can be
exploited by other academic and industrial research groups. However, academic projects
may also lead to results that are patentable or even commercially exploitable. From the
commercialization point of view, the most promising prodrug structure presented in this
thesis work is the ethylidene phosphate prodrug of propofol, for which a patent
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application was submitted in 2007. Future studies focusing on this structure are needed
in order to confirm the efficacy of the prodrug. This thesis work confirmed the
bioconversion of propofol ethylidene phosphate to propofol in vivo, but to achieve the
complete sedation of rats, the study would need to be repeated with larger doses. It
might also be worthwhile to separate the enantiomers and to evaluate the
pharmaceutical and pharmacokinetic behaviour of the enantiomers separately.
Furthermore, certain tests were not conducted due to small quantities of products
available (e.g. maximum aqueous solubility) and these do need to be performed.
Further studies with different model drugs containing hydroxyl and amine
functionalities would also expand the usefulness of this novel ethylidene phosphate
prodrug structure. The hydroxyl group of propofol is phenolic, and thus, differs from
primary, secondary and tertiary hydroxyl groups. The evaluation of ethylidene
phosphates of these structures would be interesting. Another interesting application
would be the ethylidene-linked phosphate prodrug of phenytoin, comparing to its
properties to the marketed prodrug, fosphenytoin, in which the phosphonooxymethyl
promoiety is attached to a weakly acidic amine functionality of phenytoin. In addition, a
more detailed evaluation of the monoalkyl phosphates with enhanced membrane
permeation properties would require more studies with a variety of model compounds
(e.g. those with a nucleotide-type structure) to clarify the applicability of these
structures as prodrugs.
Prodrugs have been applied to many of the most common functionalities in drug
molecules, and a large number of novel and potential prodrug structures are described in
the literature. Nonetheless, pharmaceutical companies often rely on old and familiar
structures, such as esters, when making prodrugs. If there was a large and detailed
database about the applicability of different promoieties to various functionalities, this
might encourage the researchers to select a more appropriate prodrug structure for the
desired purpose. This data could be in the form of an on-line database, e.g. where one
could quickly find all prodrug structures of a secondary hydroxyl group that enhance
aqueous solubility of a parent drug. The availability of this kind of database could
possibly make prodrugs more easily accessible to scientists less familiar with this
versatile approach to improve drug delivery.
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Prodrugs are now an established part of drug discovery and development. Several
successful prodrugs have been created with enhanced solubility and permeability
characteristics, but much work is still needed, especially in the areas of site-selective
drug delivery. Surprisingly few examples of prodrugs for cancer therapy are marketed,
even though the side-effects of the traditional anticancer agents are distressing, often
requiring premature termination of the therapy and poor compliance. Similarly, there
are relatively few marketed prodrugs for CNS-targeted drug delivery, despite the
benefits of achieving selective drug concentration into the brain in preference to other
tissues in the body. Perhaps it can be concluded that the easiest prodrugs have now been
examined and the more complex applications of prodrugs are still waiting investigation.
I believe that especially CNS and tumor targeted prodrugs will be fruitful research areas
in the future as the benefits compared to traditional therapy are so obvious.
Prodrug approach is undoubtedly a useful and versatile method in improving the poor
drug-like properties of an active drug. Nonetheless, the optimal situation in the drug
discovery and development process is, when directly active drug molecule can be used
as is and prodrugs are not needed.
128
10 SUMMARY AND CONCLUSIONS
The present study described the synthesis, in vitro and in vivo evaluation of several
prodrug structures including hydroxyimine and phosphate prodrugs. The aim of this
study was to develop synthesis routes for the novel prodrug structures and to evaluate
their capabilities to improve drug delivery. The following conclusions can be made
based on the present study:
1. The nabumetone hydroxyimine underwent microsomal CYP 450-mediated
oxidation to nabumetone in vitro and in vivo. The hydroxyimine prodrug structure
is a potential intermediate prodrug structure for ketone drugs that can easily be
derivatized to oximes using the appropriate promoieties depending on the prodrug
application. However, insufficient chemical stability and an inadequate enzymatic
bioconversion rate of the prodrugs to the active drug may limit the usefulness of
hydroxyimine or oxime structures as prodrugs.
2. A novel synthesis route to prepare 1-chloroethyl phosphates and
phosphoramidates as possible building blocks of novel ethylidene linked
phosphate prodrugs was developed. This versatile and simple route can be
conducted under NTP conditions, but increased yields, shortened reaction times
and the possibility to synthesize otherwise unavailable reaction products were
achieved with a microwave-assisted synthesis.
3. 1-Chloroethyl phosphates could not be utilized in the synthesis of ethylidene
phosphate propofol probably due to steric reasons. Instead, a similar synthesis
route using tetrabutylammonium phosphate was successfully exploited in the
synthesis of an ethylidene phosphate prodrug of propofol.
4. The ethylidene phosphate prodrug of propofol increased the aqueous solubility
of propofol and its chemical stability was sufficient to permit i.v. administration.
The enzymatic release of propofol from the prodrug was rapid both in vitro in
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alkaline phosphatase solution and in vivo in rats. These results show that
ethylidene linked phosphates are suitable water-soluble prodrugs for i.v.
administration. In general, ethylidene linked phosphates appear to be promising
water-soluble prodrug structures for achieving enhanced drug delivery.
5. The monomethylester phosphates of propofol were not enzymatically cleaved
either in vitro in solutions of alkaline phosphatase, phosphodiesterase or liver
homogenate, or in vivo in rats, probably due to the inability of propofol to act as
a substrate for phosphodiesterases. Thus, the diesters of phosphates do not seem
to be suitable as potential prodrug structures, but more studies will be needed to
confirm this conclusion.
Taken together, the results obtained in this dissertation project provide useful
information of several novel prodrug structures for future prodrug design and
development. As many new questions were raised during this work as were answered;
this reflects the challenges that exist in this fascinating area of prodrug research.
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